CA2468562C - Hydrazonopyrazole derivatives and their use as therapeutics - Google Patents
Hydrazonopyrazole derivatives and their use as therapeutics Download PDFInfo
- Publication number
- CA2468562C CA2468562C CA2468562A CA2468562A CA2468562C CA 2468562 C CA2468562 C CA 2468562C CA 2468562 A CA2468562 A CA 2468562A CA 2468562 A CA2468562 A CA 2468562A CA 2468562 C CA2468562 C CA 2468562C
- Authority
- CA
- Canada
- Prior art keywords
- pyrazol
- ylamine
- hydrazono
- phenylhydrazono
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims description 11
- HDRKIIGABIAXGC-UHFFFAOYSA-N 1H-pyrazol-5-yldiazene Chemical class N=NC1=CC=NN1 HDRKIIGABIAXGC-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 507
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 104
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 46
- 125000000217 alkyl group Chemical group 0.000 claims description 322
- 125000003118 aryl group Chemical group 0.000 claims description 275
- 239000001257 hydrogen Substances 0.000 claims description 253
- 229910052739 hydrogen Inorganic materials 0.000 claims description 253
- 125000005843 halogen group Chemical group 0.000 claims description 191
- 125000001424 substituent group Chemical group 0.000 claims description 177
- -1 isooxazolyl Chemical group 0.000 claims description 166
- 150000002431 hydrogen Chemical group 0.000 claims description 162
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 155
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 153
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 151
- 125000001188 haloalkyl group Chemical group 0.000 claims description 140
- 239000000203 mixture Substances 0.000 claims description 117
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 111
- 125000000623 heterocyclic group Chemical group 0.000 claims description 100
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 90
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 89
- 125000003545 alkoxy group Chemical group 0.000 claims description 71
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 65
- 125000002947 alkylene group Chemical group 0.000 claims description 57
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 52
- 125000005638 hydrazono group Chemical group 0.000 claims description 43
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 37
- 150000003839 salts Chemical class 0.000 claims description 34
- 210000004027 cell Anatomy 0.000 claims description 31
- 125000004995 haloalkylthio group Chemical group 0.000 claims description 24
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 23
- 125000005164 aryl thioalkyl group Chemical group 0.000 claims description 22
- 208000035475 disorder Diseases 0.000 claims description 22
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims description 19
- 239000012453 solvate Substances 0.000 claims description 19
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 18
- 125000004076 pyridyl group Chemical group 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims description 17
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 16
- 125000003342 alkenyl group Chemical group 0.000 claims description 14
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 14
- 208000017169 kidney disease Diseases 0.000 claims description 13
- 125000003386 piperidinyl group Chemical group 0.000 claims description 13
- 230000002401 inhibitory effect Effects 0.000 claims description 12
- 125000002757 morpholinyl group Chemical group 0.000 claims description 12
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 12
- 206010061218 Inflammation Diseases 0.000 claims description 11
- 230000004054 inflammatory process Effects 0.000 claims description 11
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 10
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 9
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 9
- 125000000335 thiazolyl group Chemical group 0.000 claims description 9
- PRFCJSJLZZUTMW-UHFFFAOYSA-N (4e)-4-(phenylhydrazinylidene)-5-pyridin-4-ylpyrazol-3-amine Chemical compound NC1=NN=C(C=2C=CN=CC=2)C1=NNC1=CC=CC=C1 PRFCJSJLZZUTMW-UHFFFAOYSA-N 0.000 claims description 8
- VVBFKBYTQJBTPB-UHFFFAOYSA-N (4e)-4-[(3-fluorophenyl)hydrazinylidene]-5-pyridin-4-ylpyrazol-3-amine Chemical compound NC1=NN=C(C=2C=CN=CC=2)C1=NNC1=CC=CC(F)=C1 VVBFKBYTQJBTPB-UHFFFAOYSA-N 0.000 claims description 8
- OUKNLVQNIFYFDZ-UHFFFAOYSA-N (4e)-5-(furan-2-yl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound NC1=NN=C(C=2OC=CC=2)\C1=N\NC1=CC=CC=C1 OUKNLVQNIFYFDZ-UHFFFAOYSA-N 0.000 claims description 8
- LBAPEKNSFCQQPK-UHFFFAOYSA-N 4-(phenylhydrazinylidene)-5-thiophen-3-ylpyrazol-3-amine Chemical compound NC1=NN=C(C2=CSC=C2)C1=NNC1=CC=CC=C1 LBAPEKNSFCQQPK-UHFFFAOYSA-N 0.000 claims description 8
- VMFBFJXRWNIGBQ-UHFFFAOYSA-N 4-[(3-fluorophenyl)hydrazinylidene]-5-(furan-2-yl)pyrazol-3-amine Chemical compound NC1=NN=C(C=2OC=CC=2)C1=NNC1=CC=CC(F)=C1 VMFBFJXRWNIGBQ-UHFFFAOYSA-N 0.000 claims description 8
- RCBOHFIBUYSRBK-UHFFFAOYSA-N 5-(4-nitrophenyl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound NC1=NN=C(C=2C=CC(=CC=2)[N+]([O-])=O)C1=NNC1=CC=CC=C1 RCBOHFIBUYSRBK-UHFFFAOYSA-N 0.000 claims description 8
- 125000004450 alkenylene group Chemical group 0.000 claims description 8
- 125000004414 alkyl thio group Chemical group 0.000 claims description 8
- INSWERQZXYQHHB-UHFFFAOYSA-N n-[(e)-(3-amino-5-pyridin-4-ylpyrazol-4-ylidene)amino]pyridin-3-amine Chemical compound NC1=NN=C(C=2C=CN=CC=2)C1=NNC1=CC=CN=C1 INSWERQZXYQHHB-UHFFFAOYSA-N 0.000 claims description 8
- QRYYAPCZCVPHIA-UHFFFAOYSA-N n-[(e)-[3-amino-5-(1-methylpyrrol-2-yl)pyrazol-4-ylidene]amino]pyridin-3-amine Chemical compound CN1C=CC=C1C1=NN=C(N)C1=NNC1=CC=CN=C1 QRYYAPCZCVPHIA-UHFFFAOYSA-N 0.000 claims description 8
- ZBHCUEQBXAPHAA-UHFFFAOYSA-N n-[(e)-[3-amino-5-[(4-methoxyphenyl)methyl]pyrazol-4-ylidene]amino]pyridin-3-amine Chemical compound C1=CC(OC)=CC=C1CC1=NN=C(N)C1=NNC1=CC=CN=C1 ZBHCUEQBXAPHAA-UHFFFAOYSA-N 0.000 claims description 8
- SQVAOULMTNRVBX-UHFFFAOYSA-N n-[[3-amino-5-(1-methylpyrrol-2-yl)pyrazol-4-ylidene]amino]quinolin-6-amine Chemical compound CN1C=CC=C1C1=NN=C(N)C1=NNC1=CC=C(N=CC=C2)C2=C1 SQVAOULMTNRVBX-UHFFFAOYSA-N 0.000 claims description 8
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 8
- TZPCPCOGYXZHMH-UHFFFAOYSA-N (4e)-4-(phenylhydrazinylidene)-5-pyridin-3-ylpyrazol-3-amine Chemical compound NC1=NN=C(C=2C=NC=CC=2)C1=NNC1=CC=CC=C1 TZPCPCOGYXZHMH-UHFFFAOYSA-N 0.000 claims description 7
- LEVYJSOULZVOQU-UHFFFAOYSA-N 4-[[3-(morpholin-4-ylmethyl)phenyl]hydrazinylidene]-5-pyridin-4-ylpyrazol-3-amine Chemical compound NC1=NN=C(C=2C=CN=CC=2)C1=NNC(C=1)=CC=CC=1CN1CCOCC1 LEVYJSOULZVOQU-UHFFFAOYSA-N 0.000 claims description 7
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims description 7
- CCHHAHOTQJKUNT-UHFFFAOYSA-N n-[(3-amino-5-but-3-enylpyrazol-4-ylidene)amino]pyridin-3-amine Chemical compound NC1=NN=C(CCC=C)C1=NNC1=CC=CN=C1 CCHHAHOTQJKUNT-UHFFFAOYSA-N 0.000 claims description 7
- WOQXKYAYBQWQCG-UHFFFAOYSA-N n-[(3-amino-5-methylpyrazol-4-ylidene)amino]isoquinolin-5-amine Chemical compound CC1=NN=C(N)C1=NNC1=CC=CC2=CN=CC=C12 WOQXKYAYBQWQCG-UHFFFAOYSA-N 0.000 claims description 7
- GQLHFSCTSCWIRR-UHFFFAOYSA-N n-[(3-amino-5-methylpyrazol-4-ylidene)amino]phthalazin-5-amine Chemical compound CC1=NN=C(N)C1=NNC1=CC=CC2=CN=NC=C12 GQLHFSCTSCWIRR-UHFFFAOYSA-N 0.000 claims description 7
- IFIWAXWPHZTQAL-UHFFFAOYSA-N n-[(e)-(3-amino-5-pyridin-4-ylpyrazol-4-ylidene)amino]isoquinolin-5-amine Chemical compound C=1C=CC2=CN=CC=C2C=1NN=C1C(N)=NN=C1C1=CC=NC=C1 IFIWAXWPHZTQAL-UHFFFAOYSA-N 0.000 claims description 7
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 7
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 7
- FFTPRBGYDRYEPQ-UHFFFAOYSA-N (4e)-4-[(3,4-difluorophenyl)hydrazinylidene]-5-pyridin-3-ylpyrazol-3-amine Chemical compound NC1=NN=C(C=2C=NC=CC=2)C1=NNC1=CC=C(F)C(F)=C1 FFTPRBGYDRYEPQ-UHFFFAOYSA-N 0.000 claims description 6
- MEJLRQLLZPMRLF-UHFFFAOYSA-N (4e)-4-[(3-fluoro-4-methoxyphenyl)hydrazinylidene]-5-pyridin-4-ylpyrazol-3-amine Chemical compound C1=C(F)C(OC)=CC=C1NN=C1C(C=2C=CN=CC=2)=NN=C1N MEJLRQLLZPMRLF-UHFFFAOYSA-N 0.000 claims description 6
- RJQGSADMYLSRSH-UHFFFAOYSA-N (4e)-4-[(3-fluorophenyl)hydrazinylidene]-5-(3-methylphenyl)pyrazol-3-amine Chemical compound CC1=CC=CC(C=2C(C(N)=NN=2)=NNC=2C=C(F)C=CC=2)=C1 RJQGSADMYLSRSH-UHFFFAOYSA-N 0.000 claims description 6
- CTYKHPMLHJVKHX-UHFFFAOYSA-N (4e)-4-[(3-fluorophenyl)hydrazinylidene]-5-(4-methoxyphenyl)pyrazol-3-amine Chemical compound C1=CC(OC)=CC=C1C1=NN=C(N)C1=NNC1=CC=CC(F)=C1 CTYKHPMLHJVKHX-UHFFFAOYSA-N 0.000 claims description 6
- BLWZYZFDMGHETD-UHFFFAOYSA-N (4e)-4-[(3-fluorophenyl)hydrazinylidene]-5-(4-methylphenyl)pyrazol-3-amine Chemical compound C1=CC(C)=CC=C1C1=NN=C(N)C1=NNC1=CC=CC(F)=C1 BLWZYZFDMGHETD-UHFFFAOYSA-N 0.000 claims description 6
- JSENNZWOEPJIPS-UHFFFAOYSA-N (4e)-4-[(3-fluorophenyl)hydrazinylidene]-5-[3-(trifluoromethyl)phenyl]pyrazol-3-amine Chemical compound NC1=NN=C(C=2C=C(C=CC=2)C(F)(F)F)C1=NNC1=CC=CC(F)=C1 JSENNZWOEPJIPS-UHFFFAOYSA-N 0.000 claims description 6
- IWCGBBQUCCAVGA-UHFFFAOYSA-N (4e)-4-[(3-fluorophenyl)hydrazinylidene]-5-[4-(trifluoromethoxy)phenyl]pyrazol-3-amine Chemical compound NC1=NN=C(C=2C=CC(OC(F)(F)F)=CC=2)C1=NNC1=CC=CC(F)=C1 IWCGBBQUCCAVGA-UHFFFAOYSA-N 0.000 claims description 6
- MFXHPOJRBWDBBP-UHFFFAOYSA-N (4e)-5-(3-chlorophenyl)-4-[(3-fluorophenyl)hydrazinylidene]pyrazol-3-amine Chemical compound NC1=NN=C(C=2C=C(Cl)C=CC=2)C1=NNC1=CC=CC(F)=C1 MFXHPOJRBWDBBP-UHFFFAOYSA-N 0.000 claims description 6
- MSTYMZUSMKYHJL-UHFFFAOYSA-N (4e)-5-(4-chlorophenyl)-4-[(3-fluorophenyl)hydrazinylidene]pyrazol-3-amine Chemical compound NC1=NN=C(C=2C=CC(Cl)=CC=2)C1=NNC1=CC=CC(F)=C1 MSTYMZUSMKYHJL-UHFFFAOYSA-N 0.000 claims description 6
- YCCNOGZZWLCVPN-UHFFFAOYSA-N 4-[(3-fluorophenyl)hydrazinylidene]-5-(morpholin-4-ylmethyl)pyrazol-3-amine Chemical compound C=1C=CC(F)=CC=1NN=C1C(N)=NN=C1CN1CCOCC1 YCCNOGZZWLCVPN-UHFFFAOYSA-N 0.000 claims description 6
- VFMJZFJEDNQJJN-UHFFFAOYSA-N 4-[(3-fluorophenyl)hydrazinylidene]pyrazol-3-amine Chemical compound NC1=NN=CC1=NNC1=CC=CC(F)=C1 VFMJZFJEDNQJJN-UHFFFAOYSA-N 0.000 claims description 6
- 239000005541 ACE inhibitor Substances 0.000 claims description 6
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 6
- 230000009545 invasion Effects 0.000 claims description 6
- 230000005012 migration Effects 0.000 claims description 6
- 238000013508 migration Methods 0.000 claims description 6
- BKGMBCUNSUZOGU-UHFFFAOYSA-N n-[[(4z)-5-amino-4-[(3-fluorophenyl)hydrazinylidene]pyrazol-3-yl]methyl]-2-chloro-6-methylpyridine-3-carboxamide Chemical compound ClC1=NC(C)=CC=C1C(=O)NCC1=NN=C(N)C1=NNC1=CC=CC(F)=C1 BKGMBCUNSUZOGU-UHFFFAOYSA-N 0.000 claims description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 6
- VXVMOKZIUFRCLT-UHFFFAOYSA-N 4-[(3-fluoro-4-methoxyphenyl)hydrazinylidene]pyrazol-3-amine Chemical compound C1=C(F)C(OC)=CC=C1NN=C1C(N)=NN=C1 VXVMOKZIUFRCLT-UHFFFAOYSA-N 0.000 claims description 5
- JNLYBOGJWDTFMR-UHFFFAOYSA-N 5-(3-nitrophenyl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound NC1=NN=C(C=2C=C(C=CC=2)[N+]([O-])=O)C1=NNC1=CC=CC=C1 JNLYBOGJWDTFMR-UHFFFAOYSA-N 0.000 claims description 5
- NFYORNMHVKCDFC-UHFFFAOYSA-N 5-methyl-4-[(3-nitrophenyl)diazenyl]-1H-pyrazol-3-amine Chemical compound NC1=C(C(=NN1)C)N=NC1=CC(=CC=C1)[N+](=O)[O-] NFYORNMHVKCDFC-UHFFFAOYSA-N 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 125000001153 fluoro group Chemical group F* 0.000 claims description 5
- 125000002541 furyl group Chemical group 0.000 claims description 5
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 5
- 125000001544 thienyl group Chemical group 0.000 claims description 5
- YDBNPZSBUNZAOA-UHFFFAOYSA-N (4e)-4-(phenylhydrazinylidene)-5-(3,4,5-trimethoxyphenyl)pyrazol-3-amine Chemical compound COC1=C(OC)C(OC)=CC(C=2C(C(N)=NN=2)=NNC=2C=CC=CC=2)=C1 YDBNPZSBUNZAOA-UHFFFAOYSA-N 0.000 claims description 4
- JFTGDOYWQZQAKJ-UHFFFAOYSA-N (4e)-4-(phenylhydrazinylidene)-5-[2-(1,2,4-triazol-1-yl)propan-2-yl]pyrazol-3-amine Chemical compound C1=NC=NN1C(C)(C)C1=NN=C(N)C1=NNC1=CC=CC=C1 JFTGDOYWQZQAKJ-UHFFFAOYSA-N 0.000 claims description 4
- QJUMCCRSNZGICL-UHFFFAOYSA-N (4e)-4-(phenylhydrazinylidene)-5-[2-(trifluoromethoxy)phenyl]pyrazol-3-amine Chemical compound NC1=NN=C(C=2C(=CC=CC=2)OC(F)(F)F)C1=NNC1=CC=CC=C1 QJUMCCRSNZGICL-UHFFFAOYSA-N 0.000 claims description 4
- KQIRTQLHKZNPFZ-UHFFFAOYSA-N (4e)-4-(phenylhydrazinylidene)-5-[4-(trifluoromethyl)phenyl]pyrazol-3-amine Chemical compound NC1=NN=C(C=2C=CC(=CC=2)C(F)(F)F)C1=NNC1=CC=CC=C1 KQIRTQLHKZNPFZ-UHFFFAOYSA-N 0.000 claims description 4
- YVMZJHWAYVGCDJ-UHFFFAOYSA-N (4e)-4-(phenylhydrazinylidene)-5-[4-(trifluoromethylsulfanyl)phenyl]pyrazol-3-amine Chemical compound NC1=NN=C(C=2C=CC(SC(F)(F)F)=CC=2)C1=NNC1=CC=CC=C1 YVMZJHWAYVGCDJ-UHFFFAOYSA-N 0.000 claims description 4
- SUDNIPQPLNFBEW-UHFFFAOYSA-N (4e)-4-[(3,4-difluorophenyl)hydrazinylidene]-5-[(2-morpholin-4-ylethylamino)methyl]pyrazol-3-amine Chemical compound C=1C=C(F)C(F)=CC=1NN=C1C(N)=NN=C1CNCCN1CCOCC1 SUDNIPQPLNFBEW-UHFFFAOYSA-N 0.000 claims description 4
- ILGBBXVCGYONHF-UHFFFAOYSA-N (4e)-4-[(3,5-difluorophenyl)hydrazinylidene]-5-(2-phenylethyl)pyrazol-3-amine Chemical compound C=1C(F)=CC(F)=CC=1NN=C1C(N)=NN=C1CCC1=CC=CC=C1 ILGBBXVCGYONHF-UHFFFAOYSA-N 0.000 claims description 4
- MJUKGZPWBMTPDL-UHFFFAOYSA-N (4e)-4-[(3-chlorophenyl)hydrazinylidene]-5-(2-phenylethyl)pyrazol-3-amine Chemical compound C=1C=CC(Cl)=CC=1NN=C1C(N)=NN=C1CCC1=CC=CC=C1 MJUKGZPWBMTPDL-UHFFFAOYSA-N 0.000 claims description 4
- JTNRMZCRNQNDDV-UHFFFAOYSA-N (4e)-4-[(3-fluorophenyl)hydrazinylidene]-5-(2-methylfuran-3-yl)pyrazol-3-amine Chemical compound O1C=CC(C=2C(C(N)=NN=2)=NNC=2C=C(F)C=CC=2)=C1C JTNRMZCRNQNDDV-UHFFFAOYSA-N 0.000 claims description 4
- HBYITLHIDBVVIE-UHFFFAOYSA-N (4e)-4-[(3-fluorophenyl)hydrazinylidene]-5-(2-phenylethyl)pyrazol-3-amine Chemical compound C=1C=CC(F)=CC=1NN=C1C(N)=NN=C1CCC1=CC=CC=C1 HBYITLHIDBVVIE-UHFFFAOYSA-N 0.000 claims description 4
- OZINSXJBLUBVGA-UHFFFAOYSA-N (4e)-5-(2,5-dimethylfuran-3-yl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound O1C(C)=CC(C=2C(C(N)=NN=2)=NNC=2C=CC=CC=2)=C1C OZINSXJBLUBVGA-UHFFFAOYSA-N 0.000 claims description 4
- YGIADHDYZCAGCJ-UHFFFAOYSA-N (4e)-5-(2-chloro-6-methylpyridin-4-yl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound ClC1=NC(C)=CC(C=2C(C(N)=NN=2)=NNC=2C=CC=CC=2)=C1 YGIADHDYZCAGCJ-UHFFFAOYSA-N 0.000 claims description 4
- WLWREBGRDCXHJB-UHFFFAOYSA-N (4e)-5-(2-methylsulfanylpyridin-3-yl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound CSC1=NC=CC=C1C1=NN=C(N)C1=NNC1=CC=CC=C1 WLWREBGRDCXHJB-UHFFFAOYSA-N 0.000 claims description 4
- LOCZNPYOXAQMLP-UHFFFAOYSA-N (4e)-5-(2-tert-butyl-5-methylfuran-3-yl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound O1C(C)=CC(C=2C(C(N)=NN=2)=NNC=2C=CC=CC=2)=C1C(C)(C)C LOCZNPYOXAQMLP-UHFFFAOYSA-N 0.000 claims description 4
- COUMTWLLHZIMFT-UHFFFAOYSA-N (4e)-5-(3,5-dimethyl-1,2-oxazol-4-yl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound CC1=NOC(C)=C1C1=NN=C(N)C1=NNC1=CC=CC=C1 COUMTWLLHZIMFT-UHFFFAOYSA-N 0.000 claims description 4
- ZPEOSHYDLAYPLW-UHFFFAOYSA-N (4e)-5-(3-fluoro-4-methylphenyl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound C1=C(F)C(C)=CC=C1C1=NN=C(N)C1=NNC1=CC=CC=C1 ZPEOSHYDLAYPLW-UHFFFAOYSA-N 0.000 claims description 4
- ZTQFOYSYQJROBY-UHFFFAOYSA-N (4e)-5-(4-chloro-3-nitrophenyl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound NC1=NN=C(C=2C=C(C(Cl)=CC=2)[N+]([O-])=O)C1=NNC1=CC=CC=C1 ZTQFOYSYQJROBY-UHFFFAOYSA-N 0.000 claims description 4
- VTAOTWNTJNRLFD-UHFFFAOYSA-N (4e)-5-(4-fluoro-3-methylphenyl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound C1=C(F)C(C)=CC(C=2C(C(N)=NN=2)=NNC=2C=CC=CC=2)=C1 VTAOTWNTJNRLFD-UHFFFAOYSA-N 0.000 claims description 4
- AVOVQBASOARMBG-UHFFFAOYSA-N (4e)-5-(4-methylthiadiazol-5-yl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound N1=NSC(C=2C(C(N)=NN=2)=NNC=2C=CC=CC=2)=C1C AVOVQBASOARMBG-UHFFFAOYSA-N 0.000 claims description 4
- XWFZUCJHHFCIMK-UHFFFAOYSA-N (4e)-5-(5-methyl-3-phenyl-1,2-oxazol-4-yl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=NN=C(N)C1=NNC1=CC=CC=C1 XWFZUCJHHFCIMK-UHFFFAOYSA-N 0.000 claims description 4
- GQYKYEDGUIXFGO-UHFFFAOYSA-N (4e)-5-[(2,5-dimethoxyphenyl)methyl]-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound COC1=CC=C(OC)C(CC=2C(C(N)=NN=2)=NNC=2C=CC=CC=2)=C1 GQYKYEDGUIXFGO-UHFFFAOYSA-N 0.000 claims description 4
- RHWBTQICPVAUBG-UHFFFAOYSA-N (4e)-5-[(3,4-dimethoxyphenyl)methyl]-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NN=C(N)C1=NNC1=CC=CC=C1 RHWBTQICPVAUBG-UHFFFAOYSA-N 0.000 claims description 4
- QXTQLQNFIGATOA-UHFFFAOYSA-N (4e)-5-[(3-ethylphenyl)methyl]-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound CCC1=CC=CC(CC=2C(C(N)=NN=2)=NNC=2C=CC=CC=2)=C1 QXTQLQNFIGATOA-UHFFFAOYSA-N 0.000 claims description 4
- GBKCVEYCQNFMQO-UHFFFAOYSA-N (4e)-5-[(4-chlorophenoxy)methyl]-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound C=1C=CC=CC=1NN=C1C(N)=NN=C1COC1=CC=C(Cl)C=C1 GBKCVEYCQNFMQO-UHFFFAOYSA-N 0.000 claims description 4
- TVKZJBZHQAVLBO-UHFFFAOYSA-N (4e)-5-[(4-chlorophenyl)methyl]-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound C=1C=CC=CC=1NN=C1C(N)=NN=C1CC1=CC=C(Cl)C=C1 TVKZJBZHQAVLBO-UHFFFAOYSA-N 0.000 claims description 4
- KTDQFQDYXNANBS-UHFFFAOYSA-N (4e)-5-[5-(4-chlorophenyl)-2-methylfuran-3-yl]-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound CC=1OC(C=2C=CC(Cl)=CC=2)=CC=1C1=NN=C(N)C1=NNC1=CC=CC=C1 KTDQFQDYXNANBS-UHFFFAOYSA-N 0.000 claims description 4
- NYVBSUZMDDLGAM-UHFFFAOYSA-N (4e)-5-[5-methyl-2-(trifluoromethyl)furan-3-yl]-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound O1C(C)=CC(C=2C(C(N)=NN=2)=NNC=2C=CC=CC=2)=C1C(F)(F)F NYVBSUZMDDLGAM-UHFFFAOYSA-N 0.000 claims description 4
- NMTUUINPFLYHGN-UHFFFAOYSA-N (4e)-5-but-3-enyl-4-[(3,4-difluorophenyl)hydrazinylidene]pyrazol-3-amine Chemical compound NC1=NN=C(CCC=C)C1=NNC1=CC=C(F)C(F)=C1 NMTUUINPFLYHGN-UHFFFAOYSA-N 0.000 claims description 4
- GBQCLQKRJCEAJM-UHFFFAOYSA-N (4e)-5-tert-butyl-4-[(3-fluorophenyl)hydrazinylidene]pyrazol-3-amine Chemical compound CC(C)(C)C1=NN=C(N)C1=NNC1=CC=CC(F)=C1 GBQCLQKRJCEAJM-UHFFFAOYSA-N 0.000 claims description 4
- DPIPLMSIQDRZOB-UHFFFAOYSA-N (4z)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound NC1=NN=CC1=NNC1=CC=CC=C1 DPIPLMSIQDRZOB-UHFFFAOYSA-N 0.000 claims description 4
- PROOHIIQOMJJOW-UHFFFAOYSA-N (4z)-4-[(3-fluoro-4-methoxyphenyl)hydrazinylidene]-5-morpholin-4-ylpyrazol-3-amine Chemical compound C1=C(F)C(OC)=CC=C1NN=C1C(N2CCOCC2)=NN=C1N PROOHIIQOMJJOW-UHFFFAOYSA-N 0.000 claims description 4
- ADBBBUWPMMTYAD-UHFFFAOYSA-N (4z)-5-(2,1,3-benzoxadiazol-5-yl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound NC1=NN=C(C2=CC3=NON=C3C=C2)C1=NNC1=CC=CC=C1 ADBBBUWPMMTYAD-UHFFFAOYSA-N 0.000 claims description 4
- VSIAGGSUJFVBTK-UHFFFAOYSA-N 2-[[(4z)-5-amino-4-[(3,4-difluorophenyl)hydrazinylidene]pyrazol-3-yl]methyl]isoindole-1,3-dione Chemical compound NC1=NN=C(CN2C(C3=CC=CC=C3C2=O)=O)C1=NNC1=CC=C(F)C(F)=C1 VSIAGGSUJFVBTK-UHFFFAOYSA-N 0.000 claims description 4
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- MSHWXTQSDLSBDZ-UHFFFAOYSA-N 4-(phenylhydrazinylidene)-5-(1-phenyl-5-propylpyrazol-4-yl)pyrazol-3-amine Chemical compound CCCC1=C(C=2C(C(N)=NN=2)=NNC=2C=CC=CC=2)C=NN1C1=CC=CC=C1 MSHWXTQSDLSBDZ-UHFFFAOYSA-N 0.000 claims description 4
- PGAKGOHRQDUCHZ-UHFFFAOYSA-N 4-(phenylhydrazinylidene)-5-propan-2-ylpyrazol-3-amine Chemical compound CC(C)C1=NN=C(N)C1=NNC1=CC=CC=C1 PGAKGOHRQDUCHZ-UHFFFAOYSA-N 0.000 claims description 4
- DVLVZCQECXFKAN-UHFFFAOYSA-N 4-(phenylhydrazinylidene)-5-quinoxalin-2-ylpyrazol-3-amine Chemical compound NC1=NN=C(C=2N=C3C=CC=CC3=NC=2)C1=NNC1=CC=CC=C1 DVLVZCQECXFKAN-UHFFFAOYSA-N 0.000 claims description 4
- WZRHAXSZFLFKOJ-UHFFFAOYSA-N 4-[(3,4-difluorophenyl)hydrazinylidene]-5-(morpholin-4-ylmethyl)pyrazol-3-amine Chemical compound C=1C=C(F)C(F)=CC=1NN=C1C(N)=NN=C1CN1CCOCC1 WZRHAXSZFLFKOJ-UHFFFAOYSA-N 0.000 claims description 4
- NONAXIPALYRROA-UHFFFAOYSA-N 4-[(3,4-difluorophenyl)hydrazinylidene]-5-methylpyrazol-3-amine Chemical compound CC1=NN=C(N)C1=NNC1=CC=C(F)C(F)=C1 NONAXIPALYRROA-UHFFFAOYSA-N 0.000 claims description 4
- VHPBXKINPYICLL-UHFFFAOYSA-N 4-[(3-fluorophenyl)hydrazinylidene]-5-(3-morpholin-4-ylpropyl)pyrazol-3-amine Chemical compound C=1C=CC(F)=CC=1NN=C1C(N)=NN=C1CCCN1CCOCC1 VHPBXKINPYICLL-UHFFFAOYSA-N 0.000 claims description 4
- AVZANNIQDODVPK-UHFFFAOYSA-N 4-[(4z)-5-amino-4-[(3-fluorophenyl)hydrazinylidene]pyrazol-3-yl]benzoic acid Chemical compound NC1=NN=C(C=2C=CC(=CC=2)C(O)=O)C1=NNC1=CC=CC(F)=C1 AVZANNIQDODVPK-UHFFFAOYSA-N 0.000 claims description 4
- LKOCQSBVIKJBCY-UHFFFAOYSA-N 4-[[5-amino-4-[(3-fluorophenyl)hydrazinylidene]pyrazol-3-yl]methylamino]-4-oxobut-2-enoic acid Chemical compound NC1=NN=C(CNC(=O)C=CC(O)=O)C1=NNC1=CC=CC(F)=C1 LKOCQSBVIKJBCY-UHFFFAOYSA-N 0.000 claims description 4
- FICPEKCRSCJDBN-UHFFFAOYSA-N 4-[[5-amino-4-[(3-fluorophenyl)hydrazinylidene]pyrazol-3-yl]methylamino]-4-oxobutanoic acid Chemical compound NC1=NN=C(CNC(=O)CCC(O)=O)C1=NNC1=CC=CC(F)=C1 FICPEKCRSCJDBN-UHFFFAOYSA-N 0.000 claims description 4
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 4
- RTFWUSQIRVGRFW-UHFFFAOYSA-N 5-(1,3-benzodioxol-5-yl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound NC1=NN=C(C=2C=C3OCOC3=CC=2)C1=NNC1=CC=CC=C1 RTFWUSQIRVGRFW-UHFFFAOYSA-N 0.000 claims description 4
- RSHYOOHKYMQVFK-UHFFFAOYSA-N 5-(1-benzothiophen-3-yl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound NC1=NN=C(C=2C3=CC=CC=C3SC=2)C1=NNC1=CC=CC=C1 RSHYOOHKYMQVFK-UHFFFAOYSA-N 0.000 claims description 4
- NZXTYBMRFRSNSG-UHFFFAOYSA-N 5-(1-methylpyrrol-2-yl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound CN1C=CC=C1C1=NN=C(N)C1=NNC1=CC=CC=C1 NZXTYBMRFRSNSG-UHFFFAOYSA-N 0.000 claims description 4
- FMGBOROHMSNDQG-UHFFFAOYSA-N 5-(2,2-dimethylpropyl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound CC(C)(C)CC1=NN=C(N)C1=NNC1=CC=CC=C1 FMGBOROHMSNDQG-UHFFFAOYSA-N 0.000 claims description 4
- LYGMVGKVXYITHJ-UHFFFAOYSA-N 5-(2,5-dimethylpyrazol-3-yl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound CN1N=C(C)C=C1C1=NN=C(N)C1=NNC1=CC=CC=C1 LYGMVGKVXYITHJ-UHFFFAOYSA-N 0.000 claims description 4
- OVBJQXQGUVDTNZ-UHFFFAOYSA-N 5-(2-chloropyridin-4-yl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound NC1=NN=C(C=2C=C(Cl)N=CC=2)C1=NNC1=CC=CC=C1 OVBJQXQGUVDTNZ-UHFFFAOYSA-N 0.000 claims description 4
- QQTMQNZCRUHENH-UHFFFAOYSA-N 5-(2-fluorophenyl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound NC1=NN=C(C=2C(=CC=CC=2)F)C1=NNC1=CC=CC=C1 QQTMQNZCRUHENH-UHFFFAOYSA-N 0.000 claims description 4
- YRPYCIYRKPMPCH-UHFFFAOYSA-N 5-(2-methylfuran-3-yl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound O1C=CC(C=2C(C(N)=NN=2)=NNC=2C=CC=CC=2)=C1C YRPYCIYRKPMPCH-UHFFFAOYSA-N 0.000 claims description 4
- JJFHOHRRRNENSP-UHFFFAOYSA-N 5-(2-methylsulfanylethyl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound CSCCC1=NN=C(N)C1=NNC1=CC=CC=C1 JJFHOHRRRNENSP-UHFFFAOYSA-N 0.000 claims description 4
- BBCKFPPMFXXVAS-UHFFFAOYSA-N 5-(2-morpholin-4-ylethyl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound C=1C=CC=CC=1NN=C1C(N)=NN=C1CCN1CCOCC1 BBCKFPPMFXXVAS-UHFFFAOYSA-N 0.000 claims description 4
- YXERFNGILJXRSV-UHFFFAOYSA-N 5-(2-nitrophenyl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound NC1=NN=C(C=2C(=CC=CC=2)[N+]([O-])=O)C1=NNC1=CC=CC=C1 YXERFNGILJXRSV-UHFFFAOYSA-N 0.000 claims description 4
- OACMZUMBPDAWPN-UHFFFAOYSA-N 5-(2-phenylethyl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound C=1C=CC=CC=1NN=C1C(N)=NN=C1CCC1=CC=CC=C1 OACMZUMBPDAWPN-UHFFFAOYSA-N 0.000 claims description 4
- LKSMLPDFAGBCMJ-UHFFFAOYSA-N 5-(3,4-difluorophenyl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound NC1=NN=C(C=2C=C(F)C(F)=CC=2)C1=NNC1=CC=CC=C1 LKSMLPDFAGBCMJ-UHFFFAOYSA-N 0.000 claims description 4
- JVKCPNUQQNCTON-UHFFFAOYSA-N 5-(3,4-dimethoxyphenyl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound C1=C(OC)C(OC)=CC=C1C1=NN=C(N)C1=NNC1=CC=CC=C1 JVKCPNUQQNCTON-UHFFFAOYSA-N 0.000 claims description 4
- KTQRJDQYICVZNU-UHFFFAOYSA-N 5-(3,4-dimethylphenyl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound C1=C(C)C(C)=CC=C1C1=NN=C(N)C1=NNC1=CC=CC=C1 KTQRJDQYICVZNU-UHFFFAOYSA-N 0.000 claims description 4
- OBNQWRKOEVWXKD-UHFFFAOYSA-N 5-(3,5-difluorophenyl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound NC1=NN=C(C=2C=C(F)C=C(F)C=2)C1=NNC1=CC=CC=C1 OBNQWRKOEVWXKD-UHFFFAOYSA-N 0.000 claims description 4
- APSMFRSWHBUHNP-UHFFFAOYSA-N 5-(3-aminopropyl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound NCCCC1=NN=C(N)C1=NNC1=CC=CC=C1 APSMFRSWHBUHNP-UHFFFAOYSA-N 0.000 claims description 4
- PUYJDVDOOBULEE-UHFFFAOYSA-N 5-(3-bromophenyl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound NC1=NN=C(C=2C=C(Br)C=CC=2)C1=NNC1=CC=CC=C1 PUYJDVDOOBULEE-UHFFFAOYSA-N 0.000 claims description 4
- HYUCRXCWEVKXBQ-UHFFFAOYSA-N 5-(3-chlorothiophen-2-yl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound NC1=NN=C(C2=C(C=CS2)Cl)C1=NNC1=CC=CC=C1 HYUCRXCWEVKXBQ-UHFFFAOYSA-N 0.000 claims description 4
- HHYFJXWIXVQQRP-UHFFFAOYSA-N 5-(3-fluorophenyl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound NC1=NN=C(C=2C=C(F)C=CC=2)C1=NNC1=CC=CC=C1 HHYFJXWIXVQQRP-UHFFFAOYSA-N 0.000 claims description 4
- OQKLUOBFXVXOSV-UHFFFAOYSA-N 5-(3-methoxythiophen-2-yl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound C1=CSC(C=2C(C(N)=NN=2)=NNC=2C=CC=CC=2)=C1OC OQKLUOBFXVXOSV-UHFFFAOYSA-N 0.000 claims description 4
- WOVXHVUKVNKACF-UHFFFAOYSA-N 5-(3-phenoxypropyl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound C=1C=CC=CC=1NN=C1C(N)=NN=C1CCCOC1=CC=CC=C1 WOVXHVUKVNKACF-UHFFFAOYSA-N 0.000 claims description 4
- OKOFWLVZJMNTRB-UHFFFAOYSA-N 5-(4-fluorophenyl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound NC1=NN=C(C=2C=CC(F)=CC=2)C1=NNC1=CC=CC=C1 OKOFWLVZJMNTRB-UHFFFAOYSA-N 0.000 claims description 4
- BIHBMSNFWPUANA-UHFFFAOYSA-N 5-(4-morpholin-4-ylbutyl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound C=1C=CC=CC=1NN=C1C(N)=NN=C1CCCCN1CCOCC1 BIHBMSNFWPUANA-UHFFFAOYSA-N 0.000 claims description 4
- OCSJEQGWMRVXIL-UHFFFAOYSA-N 5-(5-bromopyridin-3-yl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound NC1=NN=C(C=2C=C(Br)C=NC=2)C1=NNC1=CC=CC=C1 OCSJEQGWMRVXIL-UHFFFAOYSA-N 0.000 claims description 4
- GUYOEHFVJCKLIN-UHFFFAOYSA-N 5-(6-chloropyridin-3-yl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound NC1=NN=C(C=2C=NC(Cl)=CC=2)C1=NNC1=CC=CC=C1 GUYOEHFVJCKLIN-UHFFFAOYSA-N 0.000 claims description 4
- GQLBDKDCIMPEDP-UHFFFAOYSA-N 5-(aminomethyl)-4-[(3-fluorophenyl)hydrazinylidene]pyrazol-3-amine Chemical compound NCC1=NN=C(N)C1=NNC1=CC=CC(F)=C1 GQLBDKDCIMPEDP-UHFFFAOYSA-N 0.000 claims description 4
- XJZZQQKWMINRLU-UHFFFAOYSA-N 5-[(4-methoxyphenyl)methyl]-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound C1=CC(OC)=CC=C1CC1=NN=C(N)\C1=N/NC1=CC=CC=C1 XJZZQQKWMINRLU-UHFFFAOYSA-N 0.000 claims description 4
- HHCQXAFFMGGVHQ-UHFFFAOYSA-N 5-[3-[(4-chlorophenyl)sulfanylmethyl]phenyl]-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound NC1=NN=C(C=2C=C(CSC=3C=CC(Cl)=CC=3)C=CC=2)C1=NNC1=CC=CC=C1 HHCQXAFFMGGVHQ-UHFFFAOYSA-N 0.000 claims description 4
- RYOXMHAFINUNGI-UHFFFAOYSA-N 5-benzhydryl-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound C=1C=CC=CC=1NN=C1C(N)=NN=C1C(C=1C=CC=CC=1)C1=CC=CC=C1 RYOXMHAFINUNGI-UHFFFAOYSA-N 0.000 claims description 4
- ITRURQXFYDMLRX-UHFFFAOYSA-N 5-cyclopropyl-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound C=1C=CC=CC=1NN=C1C(N)=NN=C1C1CC1 ITRURQXFYDMLRX-UHFFFAOYSA-N 0.000 claims description 4
- IVCGXXAZOLGWBG-UHFFFAOYSA-N 5-pentan-3-yl-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound CCC(CC)C1=NN=C(N)C1=NNC1=CC=CC=C1 IVCGXXAZOLGWBG-UHFFFAOYSA-N 0.000 claims description 4
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- UIJMKJNYZOABIN-UHFFFAOYSA-N methyl 1-[4-[[5-amino-4-[(3-fluorophenyl)hydrazinylidene]pyrazol-3-yl]methylamino]-4-oxobut-2-enoyl]pyrrolidine-2-carboxylate Chemical compound COC(=O)C1CCCN1C(=O)C=CC(=O)NCC1=NN=C(N)C1=NNC1=CC=CC(F)=C1 UIJMKJNYZOABIN-UHFFFAOYSA-N 0.000 claims description 4
- 125000006542 morpholinylalkyl group Chemical group 0.000 claims description 4
- LLTYEFXXVCSNRP-UHFFFAOYSA-N n-[(3-amino-5-but-3-enylpyrazol-4-ylidene)amino]quinolin-6-amine Chemical compound NC1=NN=C(CCC=C)C1=NNC1=CC=C(N=CC=C2)C2=C1 LLTYEFXXVCSNRP-UHFFFAOYSA-N 0.000 claims description 4
- XKXQIAGVFBYIRU-UHFFFAOYSA-N n-[(3-amino-5-cyclopropylpyrazol-4-ylidene)amino]pyridin-3-amine Chemical compound C=1C=CN=CC=1NN=C1C(N)=NN=C1C1CC1 XKXQIAGVFBYIRU-UHFFFAOYSA-N 0.000 claims description 4
- HIKHFHNJFHFKJS-UHFFFAOYSA-N n-[(3-amino-5-methylpyrazol-4-ylidene)amino]-2h-tetrazol-5-amine Chemical compound CC1=NN=C(N)C1=NNC1=NNN=N1 HIKHFHNJFHFKJS-UHFFFAOYSA-N 0.000 claims description 4
- OJGUTTDWQXPCCL-UHFFFAOYSA-N n-[(3-amino-5-thiophen-2-ylpyrazol-4-ylidene)amino]pyridin-3-amine Chemical compound NC1=NN=C(C=2SC=CC=2)C1=NNC1=CC=CN=C1 OJGUTTDWQXPCCL-UHFFFAOYSA-N 0.000 claims description 4
- ZPLWDDQWYUSABI-UHFFFAOYSA-N n-[(e)-(3-amino-5-methylpyrazol-4-ylidene)amino]-1h-1,2,4-triazol-5-amine Chemical compound CC1=NN=C(N)C1=NNC1=NN=CN1 ZPLWDDQWYUSABI-UHFFFAOYSA-N 0.000 claims description 4
- FRFDCYZFABGBGC-UHFFFAOYSA-N n-[(z)-(3-amino-5-morpholin-4-ylpyrazol-4-ylidene)amino]-6-chloropyridin-3-amine Chemical compound C=1C=C(Cl)N=CC=1NN=C1C(N)=NN=C1N1CCOCC1 FRFDCYZFABGBGC-UHFFFAOYSA-N 0.000 claims description 4
- WQDZTFYAZHLKSD-UHFFFAOYSA-N n-[(z)-(3-amino-5-morpholin-4-ylpyrazol-4-ylidene)amino]-6-methylpyridin-3-amine Chemical compound C1=NC(C)=CC=C1NN=C1C(N2CCOCC2)=NN=C1N WQDZTFYAZHLKSD-UHFFFAOYSA-N 0.000 claims description 4
- BRXNEQZUKLTHRO-UHFFFAOYSA-N n-[(z)-(3-amino-5-morpholin-4-ylpyrazol-4-ylidene)amino]phthalazin-5-amine Chemical compound C=1C=CC2=CN=NC=C2C=1NN=C1C(N)=NN=C1N1CCOCC1 BRXNEQZUKLTHRO-UHFFFAOYSA-N 0.000 claims description 4
- VBEPOKRATXIHBU-UHFFFAOYSA-N n-[(z)-(3-amino-5-morpholin-4-ylpyrazol-4-ylidene)amino]pyridin-3-amine Chemical compound C=1C=CN=CC=1NN=C1C(N)=NN=C1N1CCOCC1 VBEPOKRATXIHBU-UHFFFAOYSA-N 0.000 claims description 4
- WVMXOWXFZIBOCN-UHFFFAOYSA-N n-[(z)-(3-amino-5-pyrrolidin-1-ylpyrazol-4-ylidene)amino]-6-chloropyridin-3-amine Chemical compound C=1C=C(Cl)N=CC=1NN=C1C(N)=NN=C1N1CCCC1 WVMXOWXFZIBOCN-UHFFFAOYSA-N 0.000 claims description 4
- RROPNTBIMNIFQF-UHFFFAOYSA-N n-[(z)-(3-amino-5-pyrrolidin-1-ylpyrazol-4-ylidene)amino]-6-fluoropyridin-3-amine Chemical compound C=1C=C(F)N=CC=1NN=C1C(N)=NN=C1N1CCCC1 RROPNTBIMNIFQF-UHFFFAOYSA-N 0.000 claims description 4
- CQIKWLIAOWUKBH-UHFFFAOYSA-N n-[(z)-(3-amino-5-pyrrolidin-1-ylpyrazol-4-ylidene)amino]quinolin-6-amine Chemical compound C=1C=C2N=CC=CC2=CC=1NN=C1C(N)=NN=C1N1CCCC1 CQIKWLIAOWUKBH-UHFFFAOYSA-N 0.000 claims description 4
- HQTPRSWCMWUBDM-UHFFFAOYSA-N n-[4-[5-amino-4-(phenylhydrazinylidene)pyrazol-3-yl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=NN=C(N)C1=NNC1=CC=CC=C1 HQTPRSWCMWUBDM-UHFFFAOYSA-N 0.000 claims description 4
- DCNZHILWVACQPC-UHFFFAOYSA-N n-[[3-(methylamino)-5-pyridin-4-ylpyrazol-4-ylidene]amino]phthalazin-5-amine Chemical compound C=1C=CC2=CN=NC=C2C=1NN=C1C(NC)=NN=C1C1=CC=NC=C1 DCNZHILWVACQPC-UHFFFAOYSA-N 0.000 claims description 4
- FZVGNSBERUDGMW-UHFFFAOYSA-N n-[[3-amino-5-(2-fluorophenyl)pyrazol-4-ylidene]amino]phthalazin-5-amine Chemical compound C=1C=CC2=CN=NC=C2C=1NN=C1C(N)=NN=C1C1=CC=CC=C1F FZVGNSBERUDGMW-UHFFFAOYSA-N 0.000 claims description 4
- UNOKNGULZZDZHS-UHFFFAOYSA-N n-[[3-amino-5-(aminomethyl)pyrazol-4-ylidene]amino]isoquinolin-5-amine Chemical compound NCC1=NN=C(N)C1=NNC1=CC=CC2=CN=CC=C12 UNOKNGULZZDZHS-UHFFFAOYSA-N 0.000 claims description 4
- CQIWUZXNMIFJRR-UHFFFAOYSA-N n-[[5-amino-4-[(3,4-difluorophenyl)hydrazinylidene]pyrazol-3-yl]methyl]-2-chloro-6-methylpyridine-3-carboxamide Chemical compound ClC1=NC(C)=CC=C1C(=O)NCC1=NN=C(N)C1=NNC1=CC=C(F)C(F)=C1 CQIWUZXNMIFJRR-UHFFFAOYSA-N 0.000 claims description 4
- RSCYVUDBKJQUDQ-UHFFFAOYSA-N n-[[5-amino-4-[(3,4-difluorophenyl)hydrazinylidene]pyrazol-3-yl]methyl]pyridine-3-carboxamide Chemical compound C=1C=C(F)C(F)=CC=1NN=C1C(N)=NN=C1CNC(=O)C1=CC=CN=C1 RSCYVUDBKJQUDQ-UHFFFAOYSA-N 0.000 claims description 4
- QCCVYSKGXCVTMP-UHFFFAOYSA-N n-[[5-amino-4-[(3-fluorophenyl)hydrazinylidene]pyrazol-3-yl]methyl]butane-1-sulfonamide Chemical compound CCCCS(=O)(=O)NCC1=NN=C(N)C1=NNC1=CC=CC(F)=C1 QCCVYSKGXCVTMP-UHFFFAOYSA-N 0.000 claims description 4
- DLVJLOQCTLZYNI-UHFFFAOYSA-N n-[[5-amino-4-[(3-fluorophenyl)hydrazinylidene]pyrazol-3-yl]methyl]methanesulfonamide Chemical compound CS(=O)(=O)NCC1=NN=C(N)C1=NNC1=CC=CC(F)=C1 DLVJLOQCTLZYNI-UHFFFAOYSA-N 0.000 claims description 4
- YPDAOYWHFXXDIM-UHFFFAOYSA-N n-[[5-amino-4-[(3-fluorophenyl)hydrazinylidene]pyrazol-3-yl]methyl]pyridine-3-carboxamide Chemical compound C=1C=CC(F)=CC=1NN=C1C(N)=NN=C1CNC(=O)C1=CC=CN=C1 YPDAOYWHFXXDIM-UHFFFAOYSA-N 0.000 claims description 4
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- ZZMXYYFUWQSFEW-UHFFFAOYSA-N (4e)-4-(phenylhydrazinylidene)-5-thiophen-2-ylpyrazol-3-amine Chemical compound NC1=NN=C(C=2SC=CC=2)\C1=N\NC1=CC=CC=C1 ZZMXYYFUWQSFEW-UHFFFAOYSA-N 0.000 claims description 3
- PZGLDZIXCJYYFR-UHFFFAOYSA-N (4e)-5-[(2-nitrophenoxy)methyl]-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound C=1C=CC=CC=1NN=C1C(N)=NN=C1COC1=CC=CC=C1[N+]([O-])=O PZGLDZIXCJYYFR-UHFFFAOYSA-N 0.000 claims description 3
- ZKDOCIWZCZFECB-UHFFFAOYSA-N (4z)-4-[(3-fluorophenyl)hydrazinylidene]-5-morpholin-4-ylpyrazol-3-amine Chemical compound C=1C=CC(F)=CC=1NN=C1C(N)=NN=C1N1CCOCC1 ZKDOCIWZCZFECB-UHFFFAOYSA-N 0.000 claims description 3
- RANTYAOATOSTGC-UHFFFAOYSA-N (4z)-4-[[3-(morpholin-4-ylmethyl)phenyl]hydrazinylidene]-5-pyrrolidin-1-ylpyrazol-3-amine Chemical compound C=1C=CC(CN2CCOCC2)=CC=1NN=C1C(N)=NN=C1N1CCCC1 RANTYAOATOSTGC-UHFFFAOYSA-N 0.000 claims description 3
- LQAKZUXNMPBESM-UHFFFAOYSA-N (4z)-4-[[3-[(dimethylamino)methyl]phenyl]hydrazinylidene]-5-morpholin-4-ylpyrazol-3-amine Chemical compound CN(C)CC1=CC=CC(NN=C2C(=NN=C2N)N2CCOCC2)=C1 LQAKZUXNMPBESM-UHFFFAOYSA-N 0.000 claims description 3
- DCVWMMMKFZVEDP-UHFFFAOYSA-N 1-(cyclobutylmethyl)triazole-4-carboxylic acid Chemical compound N1=NC(C(=O)O)=CN1CC1CCC1 DCVWMMMKFZVEDP-UHFFFAOYSA-N 0.000 claims description 3
- PUUDZOFTOAALGZ-UHFFFAOYSA-N 1-[2-[[5-amino-4-[(3-fluorophenyl)hydrazinylidene]pyrazol-3-yl]methylamino]-2-oxoethyl]pyrrolidine-2-carboxylic acid Chemical compound C=1C=CC(F)=CC=1NN=C1C(N)=NN=C1CNC(=O)CN1CCCC1C(O)=O PUUDZOFTOAALGZ-UHFFFAOYSA-N 0.000 claims description 3
- MIODETWMLAEHPG-UHFFFAOYSA-N 2-[[5-amino-4-[(3-fluorophenyl)hydrazinylidene]pyrazol-3-yl]methyl]isoindole-1,3-dione Chemical compound NC1=NN=C(CN2C(C3=CC=CC=C3C2=O)=O)C1=NNC1=CC=CC(F)=C1 MIODETWMLAEHPG-UHFFFAOYSA-N 0.000 claims description 3
- HZQCHRBRMOFLHS-UHFFFAOYSA-N 4-(phenylhydrazinylidene)-5-pyridin-2-ylpyrazol-3-amine Chemical compound NC1=NN=C(C=2N=CC=CC=2)C1=NNC1=CC=CC=C1 HZQCHRBRMOFLHS-UHFFFAOYSA-N 0.000 claims description 3
- JWXRFGYPTIMAJG-UHFFFAOYSA-N 4-(phenylhydrazinylidene)-5-quinolin-6-ylpyrazol-3-amine Chemical compound NC1=NN=C(C=2C=C3C=CC=NC3=CC=2)C1=NNC1=CC=CC=C1 JWXRFGYPTIMAJG-UHFFFAOYSA-N 0.000 claims description 3
- FOXXFRSQQCTDMI-UHFFFAOYSA-N 5-(1-benzothiophen-2-yl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound NC1=NN=C(C=2SC3=CC=CC=C3C=2)C1=NNC1=CC=CC=C1 FOXXFRSQQCTDMI-UHFFFAOYSA-N 0.000 claims description 3
- QIZUDBJBKRIKQQ-UHFFFAOYSA-N 5-(2-methylpropyl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound CC(C)CC1=NN=C(N)C1=NNC1=CC=CC=C1 QIZUDBJBKRIKQQ-UHFFFAOYSA-N 0.000 claims description 3
- QZXFGQZBJQYRMH-UHFFFAOYSA-N 5-(2-phenylcyclopropyl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound C=1C=CC=CC=1NN=C1C(N)=NN=C1C1CC1C1=CC=CC=C1 QZXFGQZBJQYRMH-UHFFFAOYSA-N 0.000 claims description 3
- SUZXRXHPBRLUJT-UHFFFAOYSA-N 5-[[bis(pyridin-3-ylmethyl)amino]methyl]-4-[(3,4-difluorophenyl)hydrazinylidene]pyrazol-3-amine Chemical compound C=1C=C(F)C(F)=CC=1NN=C1C(N)=NN=C1CN(CC=1C=NC=CC=1)CC1=CC=CN=C1 SUZXRXHPBRLUJT-UHFFFAOYSA-N 0.000 claims description 3
- OGWRVLCNRLAMHT-UHFFFAOYSA-N 5-but-3-enyl-4-[(3-nitrophenyl)hydrazinylidene]pyrazol-3-amine Chemical compound NC1=NN=C(CCC=C)C1=NNC1=CC=CC([N+]([O-])=O)=C1 OGWRVLCNRLAMHT-UHFFFAOYSA-N 0.000 claims description 3
- UQQONSKFAFDDCJ-UHFFFAOYSA-N 5-ethyl-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound CCC1=NN=C(N)C1=NNC1=CC=CC=C1 UQQONSKFAFDDCJ-UHFFFAOYSA-N 0.000 claims description 3
- VUGCEFDMWBWFGM-UHFFFAOYSA-N 5-methyl-4-[[4-(trifluoromethyl)phenyl]hydrazinylidene]pyrazol-3-amine Chemical compound CC1=NN=C(N)C1=NNC1=CC=C(C(F)(F)F)C=C1 VUGCEFDMWBWFGM-UHFFFAOYSA-N 0.000 claims description 3
- JLDAPWZORHKVCL-UHFFFAOYSA-N 5-phenyl-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound NC1=NN=C(C=2C=CC=CC=2)C1=NNC1=CC=CC=C1 JLDAPWZORHKVCL-UHFFFAOYSA-N 0.000 claims description 3
- MDZWEJNAWDIQNV-UHFFFAOYSA-N benzyl 3-[[5-amino-4-[(3-fluorophenyl)hydrazinylidene]pyrazol-3-yl]methylamino]-3-oxopropanoate Chemical compound C=1C=CC(F)=CC=1NN=C1C(N)=NN=C1CNC(=O)CC(=O)OCC1=CC=CC=C1 MDZWEJNAWDIQNV-UHFFFAOYSA-N 0.000 claims description 3
- 230000012292 cell migration Effects 0.000 claims description 3
- 210000002540 macrophage Anatomy 0.000 claims description 3
- DJRQOFXIBCFYOA-UHFFFAOYSA-N methyl 1-[2-[[5-amino-4-[(3-fluorophenyl)hydrazinylidene]pyrazol-3-yl]methylamino]-2-oxoethyl]pyrrolidine-2-carboxylate Chemical compound COC(=O)C1CCCN1CC(=O)NCC1=NN=C(N)C1=NNC1=CC=CC(F)=C1 DJRQOFXIBCFYOA-UHFFFAOYSA-N 0.000 claims description 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 3
- IYOJYKTXPAJGOO-UHFFFAOYSA-N n-[(3-amino-5-but-3-enylpyrazol-4-ylidene)amino]isoquinolin-5-amine Chemical compound NC1=NN=C(CCC=C)C1=NNC1=CC=CC2=CN=CC=C12 IYOJYKTXPAJGOO-UHFFFAOYSA-N 0.000 claims description 3
- UABWIYKAHWCMSW-UHFFFAOYSA-N n-[(3-amino-5-methylpyrazol-4-ylidene)amino]pyridin-3-amine Chemical compound CC1=NN=C(N)C1=NNC1=CC=CN=C1 UABWIYKAHWCMSW-UHFFFAOYSA-N 0.000 claims description 3
- OZHMCIDXCPZBOX-UHFFFAOYSA-N n-[(e)-(3-amino-5-tert-butylpyrazol-4-ylidene)amino]-2h-tetrazol-5-amine Chemical compound CC(C)(C)C1=NN=C(N)C1=NNC1=NN=NN1 OZHMCIDXCPZBOX-UHFFFAOYSA-N 0.000 claims description 3
- SGZXTTIEHZYPIR-UHFFFAOYSA-N n-[5-phenyl-4-(phenylhydrazinylidene)pyrazol-3-yl]pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC1=NN=C(C=2C=CC=CC=2)C1=NNC1=CC=CC=C1 SGZXTTIEHZYPIR-UHFFFAOYSA-N 0.000 claims description 3
- MBRFMUGDUGBJCY-UHFFFAOYSA-N n-[[3-(2-aminoethyl)-5-methylpyrazol-4-ylidene]amino]-3,4-difluoroaniline Chemical compound CC1=NN=C(CCN)C1=NNC1=CC=C(F)C(F)=C1 MBRFMUGDUGBJCY-UHFFFAOYSA-N 0.000 claims description 3
- UNXWWHSBJUPWQP-UHFFFAOYSA-N n-[[3-(aminomethyl)-5-methylpyrazol-4-ylidene]amino]-3,4-difluoroaniline Chemical compound CC1=NN=C(CN)C1=NNC1=CC=C(F)C(F)=C1 UNXWWHSBJUPWQP-UHFFFAOYSA-N 0.000 claims description 3
- NKXOIONWDYBWPX-UHFFFAOYSA-N n-[[3-(aminomethyl)-5-methylpyrazol-4-ylidene]amino]-3-fluoroaniline Chemical compound CC1=NN=C(CN)C1=NNC1=CC=CC(F)=C1 NKXOIONWDYBWPX-UHFFFAOYSA-N 0.000 claims description 3
- SHKSUWHNCVAINX-UHFFFAOYSA-N n-[[3-amino-5-(2-phenylethyl)pyrazol-4-ylidene]amino]isoquinolin-5-amine Chemical compound C=1C=CC2=CN=CC=C2C=1NN=C1C(N)=NN=C1CCC1=CC=CC=C1 SHKSUWHNCVAINX-UHFFFAOYSA-N 0.000 claims description 3
- NABZQMUIKNFAPR-UHFFFAOYSA-N n-[[5-amino-4-[(3-fluorophenyl)hydrazinylidene]pyrazol-3-yl]methyl]pyridine-4-carboxamide Chemical compound C=1C=CC(F)=CC=1NN=C1C(N)=NN=C1CNC(=O)C1=CC=NC=C1 NABZQMUIKNFAPR-UHFFFAOYSA-N 0.000 claims description 3
- JGZLQKANBXMVQX-UHFFFAOYSA-N (4z)-5-(4-methylpiperazin-1-yl)-4-(phenylhydrazinylidene)pyrazol-3-amine;dihydrochloride Chemical compound Cl.Cl.C1CN(C)CCN1C1=NN=C(N)C1=NNC1=CC=CC=C1 JGZLQKANBXMVQX-UHFFFAOYSA-N 0.000 claims description 2
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims description 2
- FRVROFMHOJDYAX-UHFFFAOYSA-N 5-[[bis(pyridin-2-ylmethyl)amino]methyl]-4-[(3,4-difluorophenyl)hydrazinylidene]pyrazol-3-amine Chemical compound C=1C=C(F)C(F)=CC=1NN=C1C(N)=NN=C1CN(CC=1N=CC=CC=1)CC1=CC=CC=N1 FRVROFMHOJDYAX-UHFFFAOYSA-N 0.000 claims description 2
- KMFWMJHTZFAOFC-UHFFFAOYSA-N ClC=1C=C(C=CC1)NN=C1C(=NN=C1C)N.FC=1C=C(C=CC1)NN=C1C(NN=C1C)N Chemical compound ClC=1C=C(C=CC1)NN=C1C(=NN=C1C)N.FC=1C=C(C=CC1)NN=C1C(NN=C1C)N KMFWMJHTZFAOFC-UHFFFAOYSA-N 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 125000001246 bromo group Chemical group Br* 0.000 claims description 2
- ONXFQWXPSZQARI-UHFFFAOYSA-N n-(2-morpholin-4-ylethyl)-5-phenyl-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound N=1N=C(C=2C=CC=CC=2)C(=NNC=2C=CC=CC=2)C=1NCCN1CCOCC1 ONXFQWXPSZQARI-UHFFFAOYSA-N 0.000 claims description 2
- QTNBKQXNZWYBCI-UHFFFAOYSA-N n-tert-butyl-5-methyl-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound CC1=NN=C(NC(C)(C)C)C1=NNC1=CC=CC=C1 QTNBKQXNZWYBCI-UHFFFAOYSA-N 0.000 claims description 2
- 210000000440 neutrophil Anatomy 0.000 claims description 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- UZDHFBYJCWAOSA-UHFFFAOYSA-N (4e)-4-[(3,4-difluorophenyl)hydrazinylidene]-5-pyridin-4-ylpyrazol-3-amine Chemical compound NC1=NN=C(C=2C=CN=CC=2)C1=NNC1=CC=C(F)C(F)=C1 UZDHFBYJCWAOSA-UHFFFAOYSA-N 0.000 claims 2
- MSCULCOBVCVJQH-UHFFFAOYSA-N (4z)-4-[(3-fluorophenyl)hydrazinylidene]-5-pyrrolidin-1-ylpyrazol-3-amine Chemical compound C=1C=CC(F)=CC=1NN=C1C(N)=NN=C1N1CCCC1 MSCULCOBVCVJQH-UHFFFAOYSA-N 0.000 claims 2
- FWYUTMHJUBFXKP-UHFFFAOYSA-N (4z)-5-morpholin-4-yl-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound C=1C=CC=CC=1NN=C1C(N)=NN=C1N1CCOCC1 FWYUTMHJUBFXKP-UHFFFAOYSA-N 0.000 claims 2
- FNZRIAXTWKACHA-UHFFFAOYSA-N (4z)-5-pyrrolidin-1-yl-4-[[3-(pyrrolidin-1-ylmethyl)phenyl]hydrazinylidene]pyrazol-3-amine Chemical compound C=1C=CC(CN2CCCC2)=CC=1NN=C1C(N)=NN=C1N1CCCC1 FNZRIAXTWKACHA-UHFFFAOYSA-N 0.000 claims 2
- RIXHTDVXZFCKDL-UHFFFAOYSA-N (4z)-5-pyrrolidin-1-yl-4-[[3-(trifluoromethyl)phenyl]hydrazinylidene]pyrazol-3-amine Chemical compound C=1C=CC(C(F)(F)F)=CC=1NN=C1C(N)=NN=C1N1CCCC1 RIXHTDVXZFCKDL-UHFFFAOYSA-N 0.000 claims 2
- MKHWIISNBAMISG-UHFFFAOYSA-N 4-[(3-fluorophenyl)hydrazinylidene]-5-phenylpyrazol-3-amine Chemical compound NC1=NN=C(C=2C=CC=CC=2)C1=NNC1=CC=CC(F)=C1 MKHWIISNBAMISG-UHFFFAOYSA-N 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 230000004709 cell invasion Effects 0.000 claims 2
- XEIZOPMXGMKTFT-UHFFFAOYSA-N ethyl 5-[2-(3-amino-5-methylpyrazol-4-ylidene)hydrazinyl]-1h-pyrazole-4-carboxylate Chemical compound CCOC(=O)C1=CNN=C1NN=C1C(N)=NN=C1C XEIZOPMXGMKTFT-UHFFFAOYSA-N 0.000 claims 2
- YFZXAGXMBFZVOZ-UHFFFAOYSA-N methyl 4-[(4z)-5-amino-4-[(3-fluorophenyl)hydrazinylidene]pyrazol-3-yl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C1=NN=C(N)C1=NNC1=CC=CC(F)=C1 YFZXAGXMBFZVOZ-UHFFFAOYSA-N 0.000 claims 2
- NZOBHNZSJGEKNV-UHFFFAOYSA-N n-[[3-(aminomethyl)-5-pyridin-4-ylpyrazol-4-ylidene]amino]-3,4-difluoroaniline Chemical compound NCC1=NN=C(C=2C=CN=CC=2)C1=NNC1=CC=C(F)C(F)=C1 NZOBHNZSJGEKNV-UHFFFAOYSA-N 0.000 claims 2
- RFWMHXJNMOEHLK-UHFFFAOYSA-N n-[[3-(aminomethyl)-5-pyridin-4-ylpyrazol-4-ylidene]amino]-3-fluoroaniline Chemical compound NCC1=NN=C(C=2C=CN=CC=2)C1=NNC1=CC=CC(F)=C1 RFWMHXJNMOEHLK-UHFFFAOYSA-N 0.000 claims 2
- QYXKURQTXGOGPS-UHFFFAOYSA-N (4e)-4-[(3,4-difluorophenyl)hydrazinylidene]-n-ethyl-5-methylpyrazol-3-amine Chemical compound CCNC1=NN=C(C)\C1=N/NC1=CC=C(F)C(F)=C1 QYXKURQTXGOGPS-UHFFFAOYSA-N 0.000 claims 1
- OZPVEFYKDRJVCT-UHFFFAOYSA-N 4-[(3-fluorophenyl)hydrazinylidene]-3-methyl-1,5-dihydropyrazol-5-amine Chemical compound CC1=NNC(N)C1=NNC1=CC=CC(F)=C1 OZPVEFYKDRJVCT-UHFFFAOYSA-N 0.000 claims 1
- KNEGQDZQPRPGBV-UHFFFAOYSA-N 5-(aminomethyl)-4-[(3,4-difluorophenyl)hydrazinylidene]pyrazol-3-amine Chemical compound NCC1=NN=C(N)C1=NNC1=CC=C(F)C(F)=C1 KNEGQDZQPRPGBV-UHFFFAOYSA-N 0.000 claims 1
- BHEXONBGNZRDMW-UHFFFAOYSA-N 5-[(2e)-2-(3-amino-5-methylpyrazol-4-ylidene)hydrazinyl]-2h-triazole-4-carboxylic acid Chemical compound CC1=NN=C(N)C1=NNC1=NNN=C1C(O)=O BHEXONBGNZRDMW-UHFFFAOYSA-N 0.000 claims 1
- FZWNSFJETJHGAR-UHFFFAOYSA-N 5-[2-(3-amino-5-methylpyrazol-4-ylidene)hydrazinyl]-1h-pyrazole-4-carboxylic acid Chemical compound CC1=NN=C(N)C1=NNC1=NNC=C1C(O)=O FZWNSFJETJHGAR-UHFFFAOYSA-N 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- DQIKINKDVJKFKA-UHFFFAOYSA-N FC=1C=C(C=CC1)NN=C1C(=NN=C1C)NC Chemical compound FC=1C=C(C=CC1)NN=C1C(=NN=C1C)NC DQIKINKDVJKFKA-UHFFFAOYSA-N 0.000 claims 1
- QQQIAJCEOKVDKX-UHFFFAOYSA-N FC=1C=C(C=CC1F)NN=C1C(=NN=C1C)NC Chemical compound FC=1C=C(C=CC1F)NN=C1C(=NN=C1C)NC QQQIAJCEOKVDKX-UHFFFAOYSA-N 0.000 claims 1
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- GVANXOOXDGQXOG-UHFFFAOYSA-N n-[[(4z)-5-amino-4-[(3-fluorophenyl)hydrazinylidene]pyrazol-3-yl]methyl]-4-fluorobenzenesulfonamide Chemical compound C=1C=CC(F)=CC=1NN=C1C(N)=NN=C1CNS(=O)(=O)C1=CC=C(F)C=C1 GVANXOOXDGQXOG-UHFFFAOYSA-N 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 26
- 201000010099 disease Diseases 0.000 abstract description 22
- 230000003463 hyperproliferative effect Effects 0.000 abstract description 10
- 230000033115 angiogenesis Effects 0.000 abstract description 9
- 230000006907 apoptotic process Effects 0.000 abstract description 7
- 230000004614 tumor growth Effects 0.000 abstract description 5
- 150000003217 pyrazoles Chemical class 0.000 abstract description 2
- 150000003219 pyrazolines Chemical class 0.000 abstract description 2
- 230000022983 regulation of cell cycle Effects 0.000 abstract description 2
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 230000020129 regulation of cell death Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 148
- 239000007787 solid Substances 0.000 description 140
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 93
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 93
- 238000006243 chemical reaction Methods 0.000 description 71
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 67
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 54
- 238000001914 filtration Methods 0.000 description 53
- 238000002360 preparation method Methods 0.000 description 46
- 238000000034 method Methods 0.000 description 43
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 42
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 42
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 41
- 239000003085 diluting agent Substances 0.000 description 37
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 36
- 239000003937 drug carrier Substances 0.000 description 35
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 239000002244 precipitate Substances 0.000 description 32
- 239000002904 solvent Substances 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- 235000019439 ethyl acetate Nutrition 0.000 description 29
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 239000007858 starting material Substances 0.000 description 25
- 102100020944 Integrin-linked protein kinase Human genes 0.000 description 23
- 206010029113 Neovascularisation Diseases 0.000 description 23
- 108010059517 integrin-linked kinase Proteins 0.000 description 23
- 229910001868 water Inorganic materials 0.000 description 23
- 125000004093 cyano group Chemical group *C#N 0.000 description 21
- 230000000694 effects Effects 0.000 description 21
- 238000002560 therapeutic procedure Methods 0.000 description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 238000010438 heat treatment Methods 0.000 description 18
- 238000004809 thin layer chromatography Methods 0.000 description 18
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 16
- 239000000706 filtrate Substances 0.000 description 16
- 229940002612 prodrug Drugs 0.000 description 16
- 239000000651 prodrug Substances 0.000 description 16
- 238000000746 purification Methods 0.000 description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 229910052757 nitrogen Inorganic materials 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 13
- 241000124008 Mammalia Species 0.000 description 12
- 150000003254 radicals Chemical class 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- 102000001253 Protein Kinase Human genes 0.000 description 10
- 108060006633 protein kinase Proteins 0.000 description 10
- 239000007832 Na2SO4 Substances 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 102000006495 integrins Human genes 0.000 description 9
- 108010044426 integrins Proteins 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- 125000006239 protecting group Chemical group 0.000 description 9
- 230000019491 signal transduction Effects 0.000 description 9
- 229910052938 sodium sulfate Inorganic materials 0.000 description 9
- 235000011152 sodium sulphate Nutrition 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- BAVYZALUXZFZLV-UHFFFAOYSA-N mono-methylamine Natural products NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 239000007868 Raney catalyst Substances 0.000 description 7
- 229910000564 Raney nickel Inorganic materials 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 210000004087 cornea Anatomy 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 201000001441 melanoma Diseases 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 235000010288 sodium nitrite Nutrition 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- MENUYOGJCXAFFU-UHFFFAOYSA-N 2-(phenylhydrazinylidene)propanedinitrile Chemical compound N#CC(C#N)=NNC1=CC=CC=C1 MENUYOGJCXAFFU-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 150000005840 aryl radicals Chemical class 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 230000030833 cell death Effects 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 210000001508 eye Anatomy 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 125000004193 piperazinyl group Chemical group 0.000 description 6
- 238000001953 recrystallisation Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- KVHNGYMZTQXLOZ-UHFFFAOYSA-N 4-[[4-fluoro-3-(trifluoromethyl)phenyl]hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=C(F)C(C(F)(F)F)=C1 KVHNGYMZTQXLOZ-UHFFFAOYSA-N 0.000 description 5
- 241000219198 Brassica Species 0.000 description 5
- 235000003351 Brassica cretica Nutrition 0.000 description 5
- 235000003343 Brassica rupestris Nutrition 0.000 description 5
- 208000010412 Glaucoma Diseases 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 239000007943 implant Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 210000000554 iris Anatomy 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 235000010460 mustard Nutrition 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 210000001525 retina Anatomy 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- NMBWXBWFDHVLGS-UHFFFAOYSA-N 2-ethylbenzenesulfonamide Chemical compound CCC1=CC=CC=C1S(N)(=O)=O NMBWXBWFDHVLGS-UHFFFAOYSA-N 0.000 description 4
- YLUOVVHTIJCVGM-UHFFFAOYSA-N 4-(1h-indazol-5-ylhydrazinylidene)pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=C(NN=C2)C2=C1 YLUOVVHTIJCVGM-UHFFFAOYSA-N 0.000 description 4
- XUGLMWVAFSJJDF-UHFFFAOYSA-N 4-(2,1,3-benzothiadiazol-4-ylhydrazinylidene)pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=CC2=NSN=C12 XUGLMWVAFSJJDF-UHFFFAOYSA-N 0.000 description 4
- LXBFAVNHXSASKP-UHFFFAOYSA-N 4-(2,1,3-benzothiadiazol-5-ylhydrazinylidene)pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC2=NSN=C2C=C1 LXBFAVNHXSASKP-UHFFFAOYSA-N 0.000 description 4
- UKADBJVNJWDGOZ-UHFFFAOYSA-N 4-[(4-methoxy-3-nitrophenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound C1=C([N+]([O-])=O)C(OC)=CC=C1NN=C1C(N)=NN=C1N UKADBJVNJWDGOZ-UHFFFAOYSA-N 0.000 description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 description 4
- 201000009273 Endometriosis Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 206010064930 age-related macular degeneration Diseases 0.000 description 4
- 230000025164 anoikis Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 230000032823 cell division Effects 0.000 description 4
- 210000003161 choroid Anatomy 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 208000030533 eye disease Diseases 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- 206010020718 hyperplasia Diseases 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 208000002780 macular degeneration Diseases 0.000 description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- IFGLKCAHWDTUSU-UHFFFAOYSA-N (3,5-diamino-4-phenyldiazenylpyrazol-1-yl)-phenylmethanone Chemical compound NC1=C(N=NC=2C=CC=CC=2)C(N)=NN1C(=O)C1=CC=CC=C1 IFGLKCAHWDTUSU-UHFFFAOYSA-N 0.000 description 3
- BSNLVDJNPAAEPL-UHFFFAOYSA-N 1-(4-bromophenyl)-4-phenyldiazenylpyrazole-3,5-diamine Chemical compound NC1=NN(C=2C=CC(Br)=CC=2)C(N)=C1N=NC1=CC=CC=C1 BSNLVDJNPAAEPL-UHFFFAOYSA-N 0.000 description 3
- FJFLZSHCDMVTJZ-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-phenyldiazenylpyrazole-3,5-diamine Chemical compound NC1=NN(C=2C=CC(F)=CC=2)C(N)=C1N=NC1=CC=CC=C1 FJFLZSHCDMVTJZ-UHFFFAOYSA-N 0.000 description 3
- LNWXALCHPJANMJ-UHFFFAOYSA-N 1-(bromomethyl)-3-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC(CBr)=C1 LNWXALCHPJANMJ-UHFFFAOYSA-N 0.000 description 3
- XBBUTOFNIPUCSQ-UHFFFAOYSA-N 1-benzyl-4-phenyldiazenylpyrazole-3,5-diamine Chemical compound NC1=C(N=NC=2C=CC=CC=2)C(N)=NN1CC1=CC=CC=C1 XBBUTOFNIPUCSQ-UHFFFAOYSA-N 0.000 description 3
- ODJMGAMTPSAOJI-UHFFFAOYSA-N 1-methyl-4-phenyldiazenylpyrazole-3,5-diamine Chemical compound CN1N=C(N)C(N=NC=2C=CC=CC=2)=C1N ODJMGAMTPSAOJI-UHFFFAOYSA-N 0.000 description 3
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 3
- QLNDTNYYPMNYCP-UHFFFAOYSA-N 2-[3-[(2e)-2-(3-amino-5-pyridin-4-ylpyrazol-4-ylidene)hydrazinyl]phenyl]sulfonylethanol Chemical compound NC1=NN=C(C=2C=CN=CC=2)C1=NNC1=CC=CC(S(=O)(=O)CCO)=C1 QLNDTNYYPMNYCP-UHFFFAOYSA-N 0.000 description 3
- GFXPRGHVUQBRIH-UHFFFAOYSA-N 2-[[5-[2-(3,5-diaminopyrazol-4-ylidene)hydrazinyl]pyridin-2-yl]-(2-hydroxyethyl)amino]ethanol Chemical compound NC1=NN=C(N)C1=NNC1=CC=C(N(CCO)CCO)N=C1 GFXPRGHVUQBRIH-UHFFFAOYSA-N 0.000 description 3
- MWWNNNAOGWPTQY-UHFFFAOYSA-N 3-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=CC(S(Cl)(=O)=O)=C1 MWWNNNAOGWPTQY-UHFFFAOYSA-N 0.000 description 3
- VZOGFSORINPSIG-UHFFFAOYSA-N 4-(1,3-benzothiazol-2-ylhydrazinylidene)pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=NC2=CC=CC=C2S1 VZOGFSORINPSIG-UHFFFAOYSA-N 0.000 description 3
- FPODTKKZLBYTCE-UHFFFAOYSA-N 4-(1h-1,2,4-triazol-5-ylhydrazinylidene)pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=NN=CN1 FPODTKKZLBYTCE-UHFFFAOYSA-N 0.000 description 3
- SYDRIGRFPHLLIL-UHFFFAOYSA-N 4-(1h-pyrazol-5-ylhydrazinylidene)pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=NNC=C1 SYDRIGRFPHLLIL-UHFFFAOYSA-N 0.000 description 3
- VQTDROFMWROHTG-UHFFFAOYSA-N 4-(3,5-diamino-4-phenyldiazenylpyrazol-1-yl)benzoic acid Chemical compound NC1=NN(C=2C=CC(=CC=2)C(O)=O)C(N)=C1N=NC1=CC=CC=C1 VQTDROFMWROHTG-UHFFFAOYSA-N 0.000 description 3
- BLWACJKMLGVWSD-UHFFFAOYSA-N 4-(isoquinolin-5-yldiazenyl)-1-methylpyrazole-3,5-diamine Chemical compound CN1N=C(N)C(N=NC=2C3=CC=NC=C3C=CC=2)=C1N BLWACJKMLGVWSD-UHFFFAOYSA-N 0.000 description 3
- WXIDXRYWMCOAMZ-UHFFFAOYSA-N 4-(isoquinolin-5-ylhydrazinylidene)pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=CC2=CN=CC=C12 WXIDXRYWMCOAMZ-UHFFFAOYSA-N 0.000 description 3
- PLHRCOBFPLCLTB-UHFFFAOYSA-N 4-(phthalazin-5-ylhydrazinylidene)pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=CC2=CN=NC=C12 PLHRCOBFPLCLTB-UHFFFAOYSA-N 0.000 description 3
- JXSAUZNHZQMFRG-UHFFFAOYSA-N 4-(quinazolin-6-ylhydrazinylidene)pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=C(N=CN=C2)C2=C1 JXSAUZNHZQMFRG-UHFFFAOYSA-N 0.000 description 3
- AFVJBKNXMOEEDH-UHFFFAOYSA-N 4-(quinolin-3-ylhydrazinylidene)pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CN=C(C=CC=C2)C2=C1 AFVJBKNXMOEEDH-UHFFFAOYSA-N 0.000 description 3
- VPPLMIWRUDTRMX-UHFFFAOYSA-N 4-(quinolin-5-yldiazenyl)-1H-pyrazole-3,5-diamine Chemical compound NC1=NNC(N)=C1N=NC1=CC=CC2=NC=CC=C12 VPPLMIWRUDTRMX-UHFFFAOYSA-N 0.000 description 3
- VGUAVKPBURZYFP-UHFFFAOYSA-N 4-(quinolin-6-ylhydrazinylidene)pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=C(N=CC=C2)C2=C1 VGUAVKPBURZYFP-UHFFFAOYSA-N 0.000 description 3
- HVLNCWLDCPOSJM-UHFFFAOYSA-N 4-(quinolin-8-ylhydrazinylidene)pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=CC2=CC=CN=C12 HVLNCWLDCPOSJM-UHFFFAOYSA-N 0.000 description 3
- LAUVWKRSNDAGJJ-UHFFFAOYSA-N 4-[(1,1-dioxo-1-benzothiophen-6-yl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=C(C=CS2(=O)=O)C2=C1 LAUVWKRSNDAGJJ-UHFFFAOYSA-N 0.000 description 3
- SHISAUBIDDYUEF-UHFFFAOYSA-N 4-[(2,2,3,3-tetrafluoro-1,4-benzodioxin-6-yl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=C(OC(F)(F)C(F)(F)O2)C2=C1 SHISAUBIDDYUEF-UHFFFAOYSA-N 0.000 description 3
- VGTFEMDPDAWVHL-UHFFFAOYSA-N 4-[(2,2-difluoro-1,3-benzodioxol-5-yl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=C(OC(F)(F)O2)C2=C1 VGTFEMDPDAWVHL-UHFFFAOYSA-N 0.000 description 3
- ZCEIXBFAYDUGHP-UHFFFAOYSA-N 4-[(2,3,4,5,6-pentafluorophenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=C(F)C(F)=C(F)C(F)=C1F ZCEIXBFAYDUGHP-UHFFFAOYSA-N 0.000 description 3
- LEVNSQBSJWGBPB-UHFFFAOYSA-N 4-[(2,3,4-trifluorophenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=C(F)C(F)=C1F LEVNSQBSJWGBPB-UHFFFAOYSA-N 0.000 description 3
- JEQORHSNDXKPOB-UHFFFAOYSA-N 4-[(2,6-dichloropyridin-3-yl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=C(Cl)N=C1Cl JEQORHSNDXKPOB-UHFFFAOYSA-N 0.000 description 3
- UHKWZJPIWZBMBQ-UHFFFAOYSA-N 4-[(2,6-difluorophenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=C(F)C=CC=C1F UHKWZJPIWZBMBQ-UHFFFAOYSA-N 0.000 description 3
- BNZCQPDHOFTAOI-UHFFFAOYSA-N 4-[(2,6-dimethoxypyridin-3-yl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound COC1=NC(OC)=CC=C1NN=C1C(N)=NN=C1N BNZCQPDHOFTAOI-UHFFFAOYSA-N 0.000 description 3
- ZUAKKGRBCCBNST-UHFFFAOYSA-N 4-[(2-bromophenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=CC=C1Br ZUAKKGRBCCBNST-UHFFFAOYSA-N 0.000 description 3
- JDROXDHWELAGQF-UHFFFAOYSA-N 4-[(2-fluoro-4-nitrophenyl)methyl]morpholine Chemical compound FC1=CC([N+](=O)[O-])=CC=C1CN1CCOCC1 JDROXDHWELAGQF-UHFFFAOYSA-N 0.000 description 3
- IDSDDJPKGOZETE-UHFFFAOYSA-N 4-[(2-methyl-5-nitrophenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound CC1=CC=C([N+]([O-])=O)C=C1NN=C1C(N)=NN=C1N IDSDDJPKGOZETE-UHFFFAOYSA-N 0.000 description 3
- VLZPUXIGSQGLID-UHFFFAOYSA-N 4-[(2-methylbenzotriazol-5-yl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound C=1C2=NN(C)N=C2C=CC=1NN=C1C(N)=NN=C1N VLZPUXIGSQGLID-UHFFFAOYSA-N 0.000 description 3
- RLJNJAWAAPGXLH-UHFFFAOYSA-N 4-[(2-propan-2-ylphenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound CC(C)C1=CC=CC=C1NN=C1C(N)=NN=C1N RLJNJAWAAPGXLH-UHFFFAOYSA-N 0.000 description 3
- LFHCKFDGKBZVTA-UHFFFAOYSA-N 4-[(3,4-dichlorophenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=C(Cl)C(Cl)=C1 LFHCKFDGKBZVTA-UHFFFAOYSA-N 0.000 description 3
- PWEAHERYYKPSFD-UHFFFAOYSA-N 4-[(3,4-difluorophenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=C(F)C(F)=C1 PWEAHERYYKPSFD-UHFFFAOYSA-N 0.000 description 3
- KLEFDCUJYZYHSA-UHFFFAOYSA-N 4-[(3,4-dimethoxyphenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound C1=C(OC)C(OC)=CC=C1NN=C1C(N)=NN=C1N KLEFDCUJYZYHSA-UHFFFAOYSA-N 0.000 description 3
- GLBXAOTUZCTMKS-UHFFFAOYSA-N 4-[(3,5-dichlorophenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC(Cl)=CC(Cl)=C1 GLBXAOTUZCTMKS-UHFFFAOYSA-N 0.000 description 3
- SJGTVWJCHMOQAW-UHFFFAOYSA-N 4-[(3,5-difluorophenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC(F)=CC(F)=C1 SJGTVWJCHMOQAW-UHFFFAOYSA-N 0.000 description 3
- BITQYWJQUDAZDZ-UHFFFAOYSA-N 4-[(3-bromophenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=CC(Br)=C1 BITQYWJQUDAZDZ-UHFFFAOYSA-N 0.000 description 3
- NRJOBBUFSUBINP-UHFFFAOYSA-N 4-[(3-chloro-4-methoxyphenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound C1=C(Cl)C(OC)=CC=C1NN=C1C(N)=NN=C1N NRJOBBUFSUBINP-UHFFFAOYSA-N 0.000 description 3
- JCFVYHNWYLZMOJ-UHFFFAOYSA-N 4-[(3-chloro-4-morpholin-4-ylphenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC(C=C1Cl)=CC=C1N1CCOCC1 JCFVYHNWYLZMOJ-UHFFFAOYSA-N 0.000 description 3
- XESXQAOHYMNIFG-UHFFFAOYSA-N 4-[(3-ethylphenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound CCC1=CC=CC(NN=C2C(=NN=C2N)N)=C1 XESXQAOHYMNIFG-UHFFFAOYSA-N 0.000 description 3
- ZUHNSFRXVSRTDR-UHFFFAOYSA-N 4-[(3-fluoro-4-methoxyphenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound C1=C(F)C(OC)=CC=C1NN=C1C(N)=NN=C1N ZUHNSFRXVSRTDR-UHFFFAOYSA-N 0.000 description 3
- OSOIRDCVQFNKBI-UHFFFAOYSA-N 4-[(3-iodophenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=CC(I)=C1 OSOIRDCVQFNKBI-UHFFFAOYSA-N 0.000 description 3
- RNSZEDRJCFFWBL-UHFFFAOYSA-N 4-[(3-methylbenzotriazol-5-yl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound C1=C2N(C)N=NC2=CC=C1NN=C1C(N)=NN=C1N RNSZEDRJCFFWBL-UHFFFAOYSA-N 0.000 description 3
- DYCXXNQEOSLRPA-UHFFFAOYSA-N 4-[(3-methylsulfanylphenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound CSC1=CC=CC(NN=C2C(=NN=C2N)N)=C1 DYCXXNQEOSLRPA-UHFFFAOYSA-N 0.000 description 3
- SWMNDJWTLOCMPN-UHFFFAOYSA-N 4-[(3-methylsulfonylphenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound CS(=O)(=O)C1=CC=CC(NN=C2C(=NN=C2N)N)=C1 SWMNDJWTLOCMPN-UHFFFAOYSA-N 0.000 description 3
- LHMIWKGTHVHONG-UHFFFAOYSA-N 4-[(3-phenylphenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=CC(C=2C=CC=CC=2)=C1 LHMIWKGTHVHONG-UHFFFAOYSA-N 0.000 description 3
- ILUBMGCQMKKYJO-UHFFFAOYSA-N 4-[(4-anilinophenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC(C=C1)=CC=C1NC1=CC=CC=C1 ILUBMGCQMKKYJO-UHFFFAOYSA-N 0.000 description 3
- CYVYICZTQSDTOS-UHFFFAOYSA-N 4-[(4-benzylphenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC(C=C1)=CC=C1CC1=CC=CC=C1 CYVYICZTQSDTOS-UHFFFAOYSA-N 0.000 description 3
- HNFHHGGCNGLDDX-UHFFFAOYSA-N 4-[(4-bromonaphthalen-1-yl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=C(Br)C2=CC=CC=C12 HNFHHGGCNGLDDX-UHFFFAOYSA-N 0.000 description 3
- HEXGYJPHYGRRER-UHFFFAOYSA-N 4-[(4-fluorophenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=C(F)C=C1 HEXGYJPHYGRRER-UHFFFAOYSA-N 0.000 description 3
- AGBHWUBSXNFLGS-UHFFFAOYSA-N 4-[(4-iodophenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=C(I)C=C1 AGBHWUBSXNFLGS-UHFFFAOYSA-N 0.000 description 3
- ACTGZYZTMAGKBM-UHFFFAOYSA-N 4-[(4-methyl-3-morpholin-4-ylphenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound C1=C(N2CCOCC2)C(C)=CC=C1NN=C1C(N)=NN=C1N ACTGZYZTMAGKBM-UHFFFAOYSA-N 0.000 description 3
- HYVDTUJBZBTGKJ-UHFFFAOYSA-N 4-[(4-methylpyridin-3-yl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound CC1=CC=NC=C1NN=C1C(N)=NN=C1N HYVDTUJBZBTGKJ-UHFFFAOYSA-N 0.000 description 3
- VFJGWZNENMTFCI-UHFFFAOYSA-N 4-[(4-methylsulfanylphenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound C1=CC(SC)=CC=C1NN=C1C(N)=NN=C1N VFJGWZNENMTFCI-UHFFFAOYSA-N 0.000 description 3
- LVAXTFMEIFHCBR-UHFFFAOYSA-N 4-[(4-methylsulfonylphenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1NN=C1C(N)=NN=C1N LVAXTFMEIFHCBR-UHFFFAOYSA-N 0.000 description 3
- JYRJFAVMZYKBID-UHFFFAOYSA-N 4-[(4-morpholin-4-ylphenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=C(N2CCOCC2)C=C1 JYRJFAVMZYKBID-UHFFFAOYSA-N 0.000 description 3
- UUGZLZHDMUQIEJ-UHFFFAOYSA-N 4-[(4-morpholin-4-ylsulfonylphenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=C(S(=O)(=O)N2CCOCC2)C=C1 UUGZLZHDMUQIEJ-UHFFFAOYSA-N 0.000 description 3
- NZKMCRKXUOELFN-UHFFFAOYSA-N 4-[(4-phenoxyphenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC(C=C1)=CC=C1OC1=CC=CC=C1 NZKMCRKXUOELFN-UHFFFAOYSA-N 0.000 description 3
- ZVGKPZWQFQKOTD-UHFFFAOYSA-N 4-[(4-phenylphenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=C(C=2C=CC=CC=2)C=C1 ZVGKPZWQFQKOTD-UHFFFAOYSA-N 0.000 description 3
- MBDCGUWTYFSKPK-UHFFFAOYSA-N 4-[(4-piperidin-1-ylphenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=C(N2CCCCC2)C=C1 MBDCGUWTYFSKPK-UHFFFAOYSA-N 0.000 description 3
- BKMLNKMFMALHGR-UHFFFAOYSA-N 4-[(4-pyrrolidin-1-ylsulfonylphenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=C(S(=O)(=O)N2CCCC2)C=C1 BKMLNKMFMALHGR-UHFFFAOYSA-N 0.000 description 3
- LCDNRLOMCIALHQ-UHFFFAOYSA-N 4-[(5-methoxy-1,3-benzothiazol-2-yl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound N=1C2=CC(OC)=CC=C2SC=1NN=C1C(N)=NN=C1N LCDNRLOMCIALHQ-UHFFFAOYSA-N 0.000 description 3
- VNPYJZGIYBYVCZ-UHFFFAOYSA-N 4-[(6-chloropyridin-3-yl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=C(Cl)N=C1 VNPYJZGIYBYVCZ-UHFFFAOYSA-N 0.000 description 3
- KJJQTZARCNGDPP-UHFFFAOYSA-N 4-[(6-fluoropyridin-3-yl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=C(F)N=C1 KJJQTZARCNGDPP-UHFFFAOYSA-N 0.000 description 3
- BHLUYAROZQEDOZ-UHFFFAOYSA-N 4-[(6-methoxypyridin-3-yl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound C1=NC(OC)=CC=C1NN=C1C(N)=NN=C1N BHLUYAROZQEDOZ-UHFFFAOYSA-N 0.000 description 3
- IROJQICVHPPBRP-UHFFFAOYSA-N 4-[(6-morpholin-4-ylpyridin-3-yl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=C(N2CCOCC2)N=C1 IROJQICVHPPBRP-UHFFFAOYSA-N 0.000 description 3
- KKYMGLKCALSWMO-UHFFFAOYSA-N 4-[(6-piperidin-1-ylpyridin-3-yl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=C(N2CCCCC2)N=C1 KKYMGLKCALSWMO-UHFFFAOYSA-N 0.000 description 3
- VEUAEELGXHDJTG-UHFFFAOYSA-N 4-[[2-(benzenesulfonyl)phenyl]hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=CC=C1S(=O)(=O)C1=CC=CC=C1 VEUAEELGXHDJTG-UHFFFAOYSA-N 0.000 description 3
- YPCLLZPOBUFZFR-UHFFFAOYSA-N 4-[[3-(diethylaminomethyl)phenyl]hydrazinylidene]pyrazole-3,5-diamine Chemical compound CCN(CC)CC1=CC=CC(NN=C2C(=NN=C2N)N)=C1 YPCLLZPOBUFZFR-UHFFFAOYSA-N 0.000 description 3
- ZMIQHAQOBHYLAA-UHFFFAOYSA-N 4-[[3-(morpholin-4-ylmethyl)-5-nitrophenyl]hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC(CN2CCOCC2)=CC([N+]([O-])=O)=C1 ZMIQHAQOBHYLAA-UHFFFAOYSA-N 0.000 description 3
- WGHKLKZBVIICCR-UHFFFAOYSA-N 4-[[3-(morpholin-4-ylmethyl)phenyl]hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=CC(CN2CCOCC2)=C1 WGHKLKZBVIICCR-UHFFFAOYSA-N 0.000 description 3
- WHPMUGPULQQXBI-UHFFFAOYSA-N 4-[[3-(piperidin-1-ylmethyl)phenyl]hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=CC(CN2CCCCC2)=C1 WHPMUGPULQQXBI-UHFFFAOYSA-N 0.000 description 3
- VAJBUYAUWRFIRT-UHFFFAOYSA-N 4-[[3-(pyrrolidin-1-ylmethyl)phenyl]hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=CC(CN2CCCC2)=C1 VAJBUYAUWRFIRT-UHFFFAOYSA-N 0.000 description 3
- PTGIUDNMMLWFCI-UHFFFAOYSA-N 4-[[3-(trifluoromethoxy)phenyl]hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=CC(OC(F)(F)F)=C1 PTGIUDNMMLWFCI-UHFFFAOYSA-N 0.000 description 3
- SVZYIZZHGRDLDA-UHFFFAOYSA-N 4-[[3-(trifluoromethylsulfonyl)phenyl]hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=CC(S(=O)(=O)C(F)(F)F)=C1 SVZYIZZHGRDLDA-UHFFFAOYSA-N 0.000 description 3
- FTPKBUBZDIJYJG-UHFFFAOYSA-N 4-[[3-[(dimethylamino)methyl]phenyl]hydrazinylidene]pyrazole-3,5-diamine Chemical compound CN(C)CC1=CC=CC(NN=C2C(=NN=C2N)N)=C1 FTPKBUBZDIJYJG-UHFFFAOYSA-N 0.000 description 3
- HRFHJUXFZAIGHZ-UHFFFAOYSA-N 4-[[3-[2-(2-methoxyethoxy)ethoxymethyl]phenyl]hydrazinylidene]pyrazole-3,5-diamine Chemical compound COCCOCCOCC1=CC=CC(NN=C2C(=NN=C2N)N)=C1 HRFHJUXFZAIGHZ-UHFFFAOYSA-N 0.000 description 3
- QIDWETIPOWISMD-UHFFFAOYSA-N 4-[[3-fluoro-5-(trifluoromethyl)phenyl]hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC(F)=CC(C(F)(F)F)=C1 QIDWETIPOWISMD-UHFFFAOYSA-N 0.000 description 3
- BZKUNPLVLZNWBZ-UHFFFAOYSA-N 4-[[3-methoxy-5-(trifluoromethyl)phenyl]hydrazinylidene]pyrazole-3,5-diamine Chemical compound FC(F)(F)C1=CC(OC)=CC(NN=C2C(=NN=C2N)N)=C1 BZKUNPLVLZNWBZ-UHFFFAOYSA-N 0.000 description 3
- SUNWDVJWZASUOD-UHFFFAOYSA-N 4-[[3-nitro-5-(trifluoromethyl)phenyl]methyl]morpholine Chemical compound FC(F)(F)C1=CC([N+](=O)[O-])=CC(CN2CCOCC2)=C1 SUNWDVJWZASUOD-UHFFFAOYSA-N 0.000 description 3
- WDKIOMUEDUOZCK-UHFFFAOYSA-N 4-[[4-(piperidin-1-ylmethyl)phenyl]hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC(C=C1)=CC=C1CN1CCCCC1 WDKIOMUEDUOZCK-UHFFFAOYSA-N 0.000 description 3
- HZSGEKAWGQFQOA-UHFFFAOYSA-N 4-[[4-(trifluoromethyl)phenyl]diazenyl]-1H-pyrazole-3,5-diamine Chemical compound NC1=NNC(=C1N=NC1=CC=C(C=C1)C(F)(F)F)N HZSGEKAWGQFQOA-UHFFFAOYSA-N 0.000 description 3
- NSYWAIJQKAUUSD-UHFFFAOYSA-N 4-[[4-(trifluoromethylsulfonyl)phenyl]hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 NSYWAIJQKAUUSD-UHFFFAOYSA-N 0.000 description 3
- ZOCKLXGZLZGVJG-UHFFFAOYSA-N 4-[[4-[[4-(methylamino)phenyl]methyl]phenyl]hydrazinylidene]pyrazole-3,5-diamine Chemical compound C1=CC(NC)=CC=C1CC(C=C1)=CC=C1NN=C1C(N)=NN=C1N ZOCKLXGZLZGVJG-UHFFFAOYSA-N 0.000 description 3
- FGQUTFXNNJWKNA-UHFFFAOYSA-N 4-[[4-chloro-3-(trifluoromethyl)phenyl]hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=C(Cl)C(C(F)(F)F)=C1 FGQUTFXNNJWKNA-UHFFFAOYSA-N 0.000 description 3
- PPGWWRSQTVTLSI-UHFFFAOYSA-N 4-[[4-nitro-3-(trifluoromethyl)phenyl]hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 PPGWWRSQTVTLSI-UHFFFAOYSA-N 0.000 description 3
- VGKHLSWLWMNITK-UHFFFAOYSA-N 4-[[6-(4-methylpiperazin-1-yl)pyridin-3-yl]hydrazinylidene]pyrazole-3,5-diamine Chemical compound C1CN(C)CCN1C(N=C1)=CC=C1NN=C1C(N)=NN=C1N VGKHLSWLWMNITK-UHFFFAOYSA-N 0.000 description 3
- KMHJLZHSKXZCIS-UHFFFAOYSA-N 4-chloro-7-fluoropyrido[4,3-d]pyrimidine Chemical compound C1=NC(Cl)=C2C=NC(F)=CC2=N1 KMHJLZHSKXZCIS-UHFFFAOYSA-N 0.000 description 3
- OQDMHVZMVJNBGQ-UHFFFAOYSA-N 5-n-ethyl-4-(phenylhydrazinylidene)pyrazole-3,5-diamine Chemical compound CCNC1=NN=C(N)C1=NNC1=CC=CC=C1 OQDMHVZMVJNBGQ-UHFFFAOYSA-N 0.000 description 3
- TUBQABMSERJOCI-UHFFFAOYSA-N 7-[2-(3,5-diaminopyrazol-4-ylidene)hydrazinyl]-4-(trifluoromethyl)-3,4-dihydrochromen-2-one Chemical compound NC1=NN=C(N)C1=NNC1=CC=C(C(CC(=O)O2)C(F)(F)F)C2=C1 TUBQABMSERJOCI-UHFFFAOYSA-N 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 239000004342 Benzoyl peroxide Substances 0.000 description 3
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 3
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 229940030999 antipsoriatics Drugs 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 125000000928 benzodioxinyl group Chemical group O1C(=COC2=C1C=CC=C2)* 0.000 description 3
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 3
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 3
- 235000019400 benzoyl peroxide Nutrition 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- IIMNZOCCIUNMSH-UHFFFAOYSA-N chembl1401643 Chemical compound NC1=NNC(N)=C1N=NC1=CC=CC(F)=C1 IIMNZOCCIUNMSH-UHFFFAOYSA-N 0.000 description 3
- HQNMHDJCGMVDTP-UHFFFAOYSA-N chembl1440687 Chemical compound NC1=NNC(N)=C1N=NC1=CC=C(OCO2)C2=C1 HQNMHDJCGMVDTP-UHFFFAOYSA-N 0.000 description 3
- FYQUIQIJAHNRDC-UHFFFAOYSA-N chembl1516511 Chemical compound NC1=NNC(N)=C1N=NC1=CC=CC(C(F)(F)F)=C1 FYQUIQIJAHNRDC-UHFFFAOYSA-N 0.000 description 3
- LOTUARPYXHNGEY-UHFFFAOYSA-N chembl428639 Chemical compound NC1=NNC(N)=C1N=NC1=CC=CC=C1CO LOTUARPYXHNGEY-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 230000008482 dysregulation Effects 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- NUKZIEYXCIOJBZ-UHFFFAOYSA-N ethyl 3-[2-(3,5-diaminopyrazol-4-ylidene)hydrazinyl]benzoate Chemical compound CCOC(=O)C1=CC=CC(NN=C2C(=NN=C2N)N)=C1 NUKZIEYXCIOJBZ-UHFFFAOYSA-N 0.000 description 3
- NUNTZDFVKYQQHW-UHFFFAOYSA-N ethyl 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]benzoate Chemical compound CCOC(=O)C1=CC=C(C=C1)N=NC2=C(NN=C2N)N NUNTZDFVKYQQHW-UHFFFAOYSA-N 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- MXDOHXBAHAHROF-UHFFFAOYSA-N methyl 1-[2-[3,5-diamino-4-(pyridin-3-yldiazenyl)pyrazol-1-yl]-2-oxoethyl]pyrrolidine-2-carboxylate Chemical compound COC(=O)C1CCCN1CC(=O)N1C(N)=C(N=NC=2C=NC=CC=2)C(N)=N1 MXDOHXBAHAHROF-UHFFFAOYSA-N 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- YSARHNFXTXWARH-UHFFFAOYSA-N morpholin-4-yl-[3-nitro-5-(trifluoromethyl)phenyl]methanone Chemical compound FC(F)(F)C1=CC([N+](=O)[O-])=CC(C(=O)N2CCOCC2)=C1 YSARHNFXTXWARH-UHFFFAOYSA-N 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 201000003142 neovascular glaucoma Diseases 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000000649 photocoagulation Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 208000037803 restenosis Diseases 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229940087562 sodium acetate trihydrate Drugs 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000000015 thermotherapy Methods 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 230000004304 visual acuity Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- QOQKOVFSUNXURX-UHFFFAOYSA-N (3-amino-5-nitrophenyl)methanol Chemical compound NC1=CC(CO)=CC([N+]([O-])=O)=C1 QOQKOVFSUNXURX-UHFFFAOYSA-N 0.000 description 2
- KPAWZHBZOUPWOJ-UHFFFAOYSA-N (4e)-4-[(3-fluorophenyl)hydrazinylidene]-5-n,5-n-dimethylpyrazole-3,5-diamine Chemical compound CN(C)C1=NN=C(N)C1=NNC1=CC=CC(F)=C1 KPAWZHBZOUPWOJ-UHFFFAOYSA-N 0.000 description 2
- HKQRAZPAMSYFFZ-UHFFFAOYSA-N (4e)-4-[(3-fluorophenyl)hydrazinylidene]-n-methyl-5-morpholin-4-ylpyrazol-3-amine Chemical compound C=1C=CC(F)=CC=1NN=C1C(NC)=NN=C1N1CCOCC1 HKQRAZPAMSYFFZ-UHFFFAOYSA-N 0.000 description 2
- LAYBPTPWKYGAOP-UHFFFAOYSA-N (4e)-4-[(6-fluoropyridin-3-yl)hydrazinylidene]-5-n,5-n-dimethylpyrazole-3,5-diamine Chemical compound CN(C)C1=NN=C(N)C1=NNC1=CC=C(F)N=C1 LAYBPTPWKYGAOP-UHFFFAOYSA-N 0.000 description 2
- CAIMRQJIDMQSQA-UHFFFAOYSA-N (4e)-5-[[bis(2-morpholin-4-ylethyl)amino]methyl]-4-[(3,4-difluorophenyl)hydrazinylidene]pyrazol-3-amine Chemical compound C=1C=C(F)C(F)=CC=1NN=C1C(N)=NN=C1CN(CCN1CCOCC1)CCN1CCOCC1 CAIMRQJIDMQSQA-UHFFFAOYSA-N 0.000 description 2
- DUJKBGDSCQUOAM-UHFFFAOYSA-N (4e)-5-n,5-n-dimethyl-4-(phthalazin-5-ylhydrazinylidene)pyrazole-3,5-diamine Chemical compound CN(C)C1=NN=C(N)C1=NNC1=CC=CC2=CN=NC=C12 DUJKBGDSCQUOAM-UHFFFAOYSA-N 0.000 description 2
- ULZQIURMWLEDQV-UHFFFAOYSA-N (4e)-5-n,5-n-dimethyl-4-(pyridin-3-ylhydrazinylidene)pyrazole-3,5-diamine Chemical compound CN(C)C1=NN=C(N)C1=NNC1=CC=CN=C1 ULZQIURMWLEDQV-UHFFFAOYSA-N 0.000 description 2
- XMRJANUSZMWCGH-UHFFFAOYSA-N (4e)-5-n,5-n-dimethyl-4-(quinolin-6-ylhydrazinylidene)pyrazole-3,5-diamine Chemical compound CN(C)C1=NN=C(N)C1=NNC1=CC=C(N=CC=C2)C2=C1 XMRJANUSZMWCGH-UHFFFAOYSA-N 0.000 description 2
- AAUNXEUQZZAQGT-UHFFFAOYSA-N (4e)-5-n,5-n-dimethyl-4-[[3-(morpholin-4-ylmethyl)phenyl]hydrazinylidene]pyrazole-3,5-diamine Chemical compound CN(C)C1=NN=C(N)C1=NNC1=CC=CC(CN2CCOCC2)=C1 AAUNXEUQZZAQGT-UHFFFAOYSA-N 0.000 description 2
- LRYVKFIOQOXESJ-UHFFFAOYSA-N 1-[(3-nitrophenyl)methyl]piperidine Chemical compound [O-][N+](=O)C1=CC=CC(CN2CCCCC2)=C1 LRYVKFIOQOXESJ-UHFFFAOYSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 2
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 2
- NSIFWRONURKXSC-UHFFFAOYSA-N 3-(bromomethyl)-5-nitroaniline Chemical compound NC1=CC(CBr)=CC([N+]([O-])=O)=C1 NSIFWRONURKXSC-UHFFFAOYSA-N 0.000 description 2
- IHHKTIKNEDOMIK-UHFFFAOYSA-N 3-(morpholin-4-ylmethyl)aniline Chemical compound NC1=CC=CC(CN2CCOCC2)=C1 IHHKTIKNEDOMIK-UHFFFAOYSA-N 0.000 description 2
- FCEYQHRTGOEDDN-UHFFFAOYSA-N 3-[2-(3,5-diaminopyrazol-4-ylidene)hydrazinyl]-n-(2-hydroxyethyl)benzenesulfonamide Chemical compound NC1=NN=C(N)C1=NNC1=CC=CC(S(=O)(=O)NCCO)=C1 FCEYQHRTGOEDDN-UHFFFAOYSA-N 0.000 description 2
- UDGCBOJAGBIKAE-UHFFFAOYSA-N 3-[2-(3-amino-5-morpholin-4-ylpyrazol-4-ylidene)hydrazinyl]benzenesulfonamide Chemical compound C=1C=CC(S(N)(=O)=O)=CC=1NN=C1C(N)=NN=C1N1CCOCC1 UDGCBOJAGBIKAE-UHFFFAOYSA-N 0.000 description 2
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 2
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 2
- WZXJTNQYPVHJLE-UHFFFAOYSA-N 3-fluoro-4-(morpholin-4-ylmethyl)aniline Chemical compound FC1=CC(N)=CC=C1CN1CCOCC1 WZXJTNQYPVHJLE-UHFFFAOYSA-N 0.000 description 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 2
- OZKUUFRMPGKVGB-UHFFFAOYSA-N 4-(2,3-dihydro-1,4-benzodioxin-6-ylhydrazinylidene)pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=C(OCCO2)C2=C1 OZKUUFRMPGKVGB-UHFFFAOYSA-N 0.000 description 2
- NZCBFZLZEYASLT-UHFFFAOYSA-N 4-(2h-benzotriazol-5-ylhydrazinylidene)pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC2=NNN=C2C=C1 NZCBFZLZEYASLT-UHFFFAOYSA-N 0.000 description 2
- VLDGPLKMTUJZMF-UHFFFAOYSA-N 4-(naphthalen-2-ylhydrazinylidene)pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=C(C=CC=C2)C2=C1 VLDGPLKMTUJZMF-UHFFFAOYSA-N 0.000 description 2
- LPMZXOZBJJUFGG-UHFFFAOYSA-N 4-(pyridin-3-yldiazenyl)-1H-pyrazole-3,5-diamine Chemical compound NC1=NNC(N)=C1N=NC1=CC=CN=C1 LPMZXOZBJJUFGG-UHFFFAOYSA-N 0.000 description 2
- KAYRKOVMJPWDNO-UHFFFAOYSA-N 4-(pyridin-4-ylhydrazinylidene)pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=NC=C1 KAYRKOVMJPWDNO-UHFFFAOYSA-N 0.000 description 2
- FGKNJBGUMSBLLY-UHFFFAOYSA-N 4-[(1-methylbenzotriazol-5-yl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound C=1C=C2N(C)N=NC2=CC=1NN=C1C(N)=NN=C1N FGKNJBGUMSBLLY-UHFFFAOYSA-N 0.000 description 2
- RYBDYKTYLCTOPG-UHFFFAOYSA-N 4-[(2-chlorophenyl)diazenyl]-1H-pyrazole-3,5-diamine Chemical compound Nc1n[nH]c(N)c1N=Nc1ccccc1Cl RYBDYKTYLCTOPG-UHFFFAOYSA-N 0.000 description 2
- KUTLYOMFYHFOCV-UHFFFAOYSA-N 4-[(2-methyl-4-morpholin-4-ylphenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound CC1=CC(N2CCOCC2)=CC=C1NN=C1C(N)=NN=C1N KUTLYOMFYHFOCV-UHFFFAOYSA-N 0.000 description 2
- LLVAMVRACVTTTO-UHFFFAOYSA-N 4-[(3,4-difluorophenyl)hydrazinylidene]pyrazol-3-amine Chemical compound NC1=NN=CC1=NNC1=CC=C(F)C(F)=C1 LLVAMVRACVTTTO-UHFFFAOYSA-N 0.000 description 2
- PFILEHJRVJXGIF-UHFFFAOYSA-N 4-[(3-chlorophenyl)diazenyl]-1H-pyrazole-3,5-diamine Chemical compound Nc1n[nH]c(N)c1N=Nc1cccc(Cl)c1 PFILEHJRVJXGIF-UHFFFAOYSA-N 0.000 description 2
- MAXOECZSANDDDP-UHFFFAOYSA-N 4-[(3-methoxyphenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound COC1=CC=CC(NN=C2C(=NN=C2N)N)=C1 MAXOECZSANDDDP-UHFFFAOYSA-N 0.000 description 2
- MORMTYLSFKKOGP-UHFFFAOYSA-N 4-[(3-nitrophenyl)methyl]morpholine Chemical compound [O-][N+](=O)C1=CC=CC(CN2CCOCC2)=C1 MORMTYLSFKKOGP-UHFFFAOYSA-N 0.000 description 2
- JDBCFQBKQVPUGW-UHFFFAOYSA-N 4-[(3-phenoxyphenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=CC(OC=2C=CC=CC=2)=C1 JDBCFQBKQVPUGW-UHFFFAOYSA-N 0.000 description 2
- RSBGVXCEYFJUAX-UHFFFAOYSA-N 4-[(4-bromophenyl)diazenyl]-1H-pyrazole-3,5-diamine Chemical compound Nc1n[nH]c(N)c1N=Nc1ccc(Br)cc1 RSBGVXCEYFJUAX-UHFFFAOYSA-N 0.000 description 2
- XMZFUSOZTUPHRA-UHFFFAOYSA-N 4-[(4-methoxyphenyl)hydrazinylidene]-5-methylpyrazol-3-amine Chemical compound C1=CC(OC)=CC=C1NN=C1C(N)=NN=C1C XMZFUSOZTUPHRA-UHFFFAOYSA-N 0.000 description 2
- MSYZJTAIVNWEMI-UHFFFAOYSA-N 4-[(5-fluoro-2-nitrophenyl)methyl]morpholine Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1CN1CCOCC1 MSYZJTAIVNWEMI-UHFFFAOYSA-N 0.000 description 2
- VAAUYDWUHKXQLY-UHFFFAOYSA-N 4-[(9-ethylcarbazol-3-yl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound C=1C=C2N(CC)C3=CC=CC=C3C2=CC=1NN=C1C(N)=NN=C1N VAAUYDWUHKXQLY-UHFFFAOYSA-N 0.000 description 2
- ADMCEWNYPAOKFP-UHFFFAOYSA-N 4-[2-(3,5-diaminopyrazol-4-ylidene)hydrazinyl]-n-(2,6-dimethylpyrimidin-4-yl)benzenesulfonamide Chemical compound CC1=NC(C)=CC(NS(=O)(=O)C=2C=CC(NN=C3C(=NN=C3N)N)=CC=2)=N1 ADMCEWNYPAOKFP-UHFFFAOYSA-N 0.000 description 2
- VUVGJXROVOASCQ-UHFFFAOYSA-N 4-[2-(3,5-diaminopyrazol-4-ylidene)hydrazinyl]-n-ethylbenzenesulfonamide Chemical compound C1=CC(S(=O)(=O)NCC)=CC=C1NN=C1C(N)=NN=C1N VUVGJXROVOASCQ-UHFFFAOYSA-N 0.000 description 2
- USDDAUQNOXISQF-UHFFFAOYSA-N 4-[[2,3-difluoro-4-(trifluoromethyl)phenyl]hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=C(C(F)(F)F)C(F)=C1F USDDAUQNOXISQF-UHFFFAOYSA-N 0.000 description 2
- ZXCCFKRQIFPALL-UHFFFAOYSA-N 4-[[3-(morpholin-4-ylmethyl)-5-(trifluoromethyl)phenyl]hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC(CN2CCOCC2)=CC(C(F)(F)F)=C1 ZXCCFKRQIFPALL-UHFFFAOYSA-N 0.000 description 2
- HOYGPQALOHHUTF-UHFFFAOYSA-N 4-[[3-[(4-methylpiperazin-1-yl)methyl]phenyl]hydrazinylidene]pyrazole-3,5-diamine Chemical compound C1CN(C)CCN1CC1=CC=CC(NN=C2C(=NN=C2N)N)=C1 HOYGPQALOHHUTF-UHFFFAOYSA-N 0.000 description 2
- KKIQMAZVFOEUPD-UHFFFAOYSA-N 4-[[3-fluoro-4-(morpholin-4-ylmethyl)phenyl]hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC(C=C1F)=CC=C1CN1CCOCC1 KKIQMAZVFOEUPD-UHFFFAOYSA-N 0.000 description 2
- WRRTWGQFLSZBFW-UHFFFAOYSA-N 4-[[4-(2-morpholin-4-ylethyl)phenyl]hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC(C=C1)=CC=C1CCN1CCOCC1 WRRTWGQFLSZBFW-UHFFFAOYSA-N 0.000 description 2
- YZBFMEVYGFYHPT-UHFFFAOYSA-N 4-[[4-(morpholin-4-ylmethyl)phenyl]hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC(C=C1)=CC=C1CN1CCOCC1 YZBFMEVYGFYHPT-UHFFFAOYSA-N 0.000 description 2
- FJICOWBLPAPWRJ-UHFFFAOYSA-N 4-[[4-[(4-methylpiperazin-1-yl)methyl]phenyl]hydrazinylidene]pyrazole-3,5-diamine Chemical compound C1CN(C)CCN1CC(C=C1)=CC=C1NN=C1C(N)=NN=C1N FJICOWBLPAPWRJ-UHFFFAOYSA-N 0.000 description 2
- XLSVRHLNTHJXKB-UHFFFAOYSA-N 4-[[4-[2-(3,5-diaminopyrazol-4-ylidene)hydrazinyl]phenyl]methylamino]-1,2,5-thiadiazole-3-carboxamide Chemical compound NC(=O)C1=NSN=C1NCC(C=C1)=CC=C1NN=C1C(N)=NN=C1N XLSVRHLNTHJXKB-UHFFFAOYSA-N 0.000 description 2
- LSVVFCHEZSQBCU-UHFFFAOYSA-N 4-[[4-fluoro-2-(morpholin-4-ylmethyl)phenyl]hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=C(F)C=C1CN1CCOCC1 LSVVFCHEZSQBCU-UHFFFAOYSA-N 0.000 description 2
- CMJFUENRZNTBIB-UHFFFAOYSA-N 4-[[4-methoxy-3-(morpholin-4-ylmethyl)phenyl]hydrazinylidene]pyrazole-3,5-diamine Chemical compound C1=C(CN2CCOCC2)C(OC)=CC=C1NN=C1C(N)=NN=C1N CMJFUENRZNTBIB-UHFFFAOYSA-N 0.000 description 2
- ZJRXQFPQQJKZEN-UHFFFAOYSA-N 4-hydroxy-5-(hydroxymethyl)-1h-pyridin-2-one Chemical compound OCC1=CNC(O)=CC1=O ZJRXQFPQQJKZEN-UHFFFAOYSA-N 0.000 description 2
- JXRGUPLJCCDGKG-UHFFFAOYSA-N 4-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=C(S(Cl)(=O)=O)C=C1 JXRGUPLJCCDGKG-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- ILPKUPISVQDYGU-UHFFFAOYSA-N C1=C(O)C(CN(CC)CC)=CC(NN=C2C(=NN=C2N)N)=C1 Chemical compound C1=C(O)C(CN(CC)CC)=CC(NN=C2C(=NN=C2N)N)=C1 ILPKUPISVQDYGU-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010055665 Corneal neovascularisation Diseases 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 2
- 206010022941 Iridocyclitis Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 208000022873 Ocular disease Diseases 0.000 description 2
- 208000021957 Ocular injury Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical compound OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 206010038848 Retinal detachment Diseases 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038935 Retinopathy sickle cell Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 206010054880 Vascular insufficiency Diseases 0.000 description 2
- 241000282485 Vulpes vulpes Species 0.000 description 2
- YGUFMHQFLFQPPV-UHFFFAOYSA-N [3-[2-(3,5-diaminopyrazol-4-ylidene)hydrazinyl]-5-nitrophenyl]methanol Chemical compound NC1=NN=C(N)C1=NNC1=CC(CO)=CC([N+]([O-])=O)=C1 YGUFMHQFLFQPPV-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000000964 angiostatic effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 201000004612 anterior uveitis Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 230000012820 cell cycle checkpoint Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- QNRNTYHAOBVOKW-UHFFFAOYSA-N chembl1389127 Chemical compound C1=CC(OC)=CC=C1N=NC1=C(N)NN=C1N QNRNTYHAOBVOKW-UHFFFAOYSA-N 0.000 description 2
- JDBSGKGTKLQVEM-UHFFFAOYSA-N chembl1518606 Chemical compound NC1=NN(C=2C=CC=CC=2)C(N)=C1N=NC1=CC=CC=C1 JDBSGKGTKLQVEM-UHFFFAOYSA-N 0.000 description 2
- BHSCLHDQTNDXDV-UHFFFAOYSA-N chembl1589011 Chemical compound CC1=CC=CC=C1N=NC1=C(N)NN=C1N BHSCLHDQTNDXDV-UHFFFAOYSA-N 0.000 description 2
- WELGNMVJTNYIRH-UHFFFAOYSA-N chembl214475 Chemical compound NC1=NNC(N)=C1N=NC1=CC=CC(O)=C1 WELGNMVJTNYIRH-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 201000000159 corneal neovascularization Diseases 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000012259 ether extract Substances 0.000 description 2
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229940090044 injection Drugs 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 2
- 201000004614 iritis Diseases 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 208000018769 loss of vision Diseases 0.000 description 2
- 231100000864 loss of vision Toxicity 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 201000001268 lymphoproliferative syndrome Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- OUTHOLOWOBGIOX-UHFFFAOYSA-N n-butyl-3-[2-(3,5-diaminopyrazol-4-ylidene)hydrazinyl]benzenesulfonamide Chemical compound CCCCNS(=O)(=O)C1=CC=CC(NN=C2C(=NN=C2N)N)=C1 OUTHOLOWOBGIOX-UHFFFAOYSA-N 0.000 description 2
- PBZJWBZJTNKIRC-UHFFFAOYSA-N n-ethyl-4-[(3-fluorophenyl)hydrazinylidene]-5-methylpyrazol-3-amine Chemical compound CCNC1=NN=C(C)C1=NNC1=CC=CC(F)=C1 PBZJWBZJTNKIRC-UHFFFAOYSA-N 0.000 description 2
- GTUAWMBSCRFHKR-UHFFFAOYSA-N n-ethyl-4-nitrobenzenesulfonamide Chemical compound CCNS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1 GTUAWMBSCRFHKR-UHFFFAOYSA-N 0.000 description 2
- IHIJFQRUYCEKCZ-UHFFFAOYSA-N n-methyl-4-nitrobenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1 IHIJFQRUYCEKCZ-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 2
- 201000005111 ocular hyperemia Diseases 0.000 description 2
- 210000001328 optic nerve Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 238000002428 photodynamic therapy Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 208000015768 polyposis Diseases 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000004264 retinal detachment Effects 0.000 description 2
- 208000032253 retinal ischemia Diseases 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000011125 single therapy Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 208000023577 vascular insufficiency disease Diseases 0.000 description 2
- YTZALCGQUPRCGW-ZSFNYQMMSA-N verteporfin Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(CCC(=O)OC)=C(C)C(N3)=C3)=N2)C)=C(C=C)C(C)=C1C=C1C2=CC=C(C(=O)OC)[C@@H](C(=O)OC)[C@@]2(C)C3=N1 YTZALCGQUPRCGW-ZSFNYQMMSA-N 0.000 description 2
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- OJZQOQNSUZLSMV-UHFFFAOYSA-N (3-aminophenyl)methanol Chemical compound NC1=CC=CC(CO)=C1 OJZQOQNSUZLSMV-UHFFFAOYSA-N 0.000 description 1
- RGGOWBBBHWTTRE-UHFFFAOYSA-N (4-bromophenyl)hydrazine;hydron;chloride Chemical compound Cl.NNC1=CC=C(Br)C=C1 RGGOWBBBHWTTRE-UHFFFAOYSA-N 0.000 description 1
- FEKUXLUOKFSMRO-UHFFFAOYSA-N (4-fluorophenyl)hydrazine;hydron;chloride Chemical compound Cl.NNC1=CC=C(F)C=C1 FEKUXLUOKFSMRO-UHFFFAOYSA-N 0.000 description 1
- WJDWIJFTYTUPCS-UHFFFAOYSA-N (4e)-4-[(6-chloropyridin-3-yl)hydrazinylidene]-5-n,5-n-dimethylpyrazole-3,5-diamine Chemical compound CN(C)C1=NN=C(N)C1=NNC1=CC=C(Cl)N=C1 WJDWIJFTYTUPCS-UHFFFAOYSA-N 0.000 description 1
- GWFNLRMCFJZWOI-UHFFFAOYSA-N (4z)-5-(4-methylpiperazin-1-yl)-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound C1CN(C)CCN1C1=NN=C(N)\C1=N\NC1=CC=CC=C1 GWFNLRMCFJZWOI-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- ZSZXYWFCIKKZBT-IVYVYLGESA-N 1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5-trisphosphate) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)O[C@@H]1[C@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O ZSZXYWFCIKKZBT-IVYVYLGESA-N 0.000 description 1
- XGNXYCFREOZBOL-UHFFFAOYSA-N 1,3-benzodioxol-5-amine Chemical compound NC1=CC=C2OCOC2=C1 XGNXYCFREOZBOL-UHFFFAOYSA-N 0.000 description 1
- NTURQZFFJDCTMZ-UHFFFAOYSA-N 1-(2-bromoethyl)-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(CCBr)C=C1 NTURQZFFJDCTMZ-UHFFFAOYSA-N 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- QGPQRZXTIGOGIP-UHFFFAOYSA-N 1-[2-(2-methoxyethoxy)ethoxymethyl]-3-nitrobenzene Chemical compound COCCOCCOCC1=CC=CC([N+]([O-])=O)=C1 QGPQRZXTIGOGIP-UHFFFAOYSA-N 0.000 description 1
- DENZGEANZCUSLQ-UHFFFAOYSA-N 1-[3-[2-(3,5-diaminopyrazol-4-ylidene)hydrazinyl]phenyl]ethanethione Chemical compound CC(=S)C1=CC=CC(NN=C2C(=NN=C2N)N)=C1 DENZGEANZCUSLQ-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- XBTOSRUBOXQWBO-UHFFFAOYSA-N 1h-indazol-5-amine Chemical compound NC1=CC=C2NN=CC2=C1 XBTOSRUBOXQWBO-UHFFFAOYSA-N 0.000 description 1
- JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical compound NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 description 1
- KGBBJPZIDRELDP-UHFFFAOYSA-N 1h-pyrazole-3,5-diamine Chemical group NC=1C=C(N)NN=1 KGBBJPZIDRELDP-UHFFFAOYSA-N 0.000 description 1
- DRLGIZIAMHIQHL-UHFFFAOYSA-N 2,1,3-benzothiadiazol-4-amine Chemical compound NC1=CC=CC2=NSN=C12 DRLGIZIAMHIQHL-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- NOXLGCOSAFGMDV-UHFFFAOYSA-N 2,3,4,5,6-pentafluoroaniline Chemical compound NC1=C(F)C(F)=C(F)C(F)=C1F NOXLGCOSAFGMDV-UHFFFAOYSA-N 0.000 description 1
- WRDGNXCXTDDYBZ-UHFFFAOYSA-N 2,3,4-trifluoroaniline Chemical compound NC1=CC=C(F)C(F)=C1F WRDGNXCXTDDYBZ-UHFFFAOYSA-N 0.000 description 1
- ODUZJBKKYBQIBX-UHFFFAOYSA-N 2,6-difluoroaniline Chemical compound NC1=C(F)C=CC=C1F ODUZJBKKYBQIBX-UHFFFAOYSA-N 0.000 description 1
- LGPDHWRELWJWHP-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-ylhydrazinylidene)propanedinitrile Chemical compound N#CC(C#N)=NNC1=CC=C2OCOC2=C1 LGPDHWRELWJWHP-UHFFFAOYSA-N 0.000 description 1
- GFJRJDJNJGWLRU-UHFFFAOYSA-N 2-(1h-indazol-5-ylhydrazinylidene)propanedinitrile Chemical compound N#CC(C#N)=NNC1=CC=C2NN=CC2=C1 GFJRJDJNJGWLRU-UHFFFAOYSA-N 0.000 description 1
- PFCPQIUIQKEVIV-UHFFFAOYSA-N 2-(2,3-dihydro-1,4-benzodioxin-6-ylhydrazinylidene)propanedinitrile Chemical compound O1CCOC2=CC(NN=C(C#N)C#N)=CC=C21 PFCPQIUIQKEVIV-UHFFFAOYSA-N 0.000 description 1
- JBCUKQQIWSWEOK-UHFFFAOYSA-N 2-(benzenesulfonyl)aniline Chemical compound NC1=CC=CC=C1S(=O)(=O)C1=CC=CC=C1 JBCUKQQIWSWEOK-UHFFFAOYSA-N 0.000 description 1
- XJMIDWRIJZXPHW-UHFFFAOYSA-N 2-(naphthalen-2-ylhydrazinylidene)propanedinitrile Chemical compound C1=CC=CC2=CC(NN=C(C#N)C#N)=CC=C21 XJMIDWRIJZXPHW-UHFFFAOYSA-N 0.000 description 1
- HHZAIEGFTSQCRW-UHFFFAOYSA-N 2-(pyridin-3-ylhydrazinylidene)propanedinitrile Chemical compound N#CC(C#N)=NNC1=CC=CN=C1 HHZAIEGFTSQCRW-UHFFFAOYSA-N 0.000 description 1
- UGLQRYVEXMABIY-UHFFFAOYSA-N 2-(quinolin-6-ylhydrazinylidene)propanedinitrile Chemical compound N1=CC=CC2=CC(NN=C(C#N)C#N)=CC=C21 UGLQRYVEXMABIY-UHFFFAOYSA-N 0.000 description 1
- YKOLZVXSPGIIBJ-UHFFFAOYSA-N 2-Isopropylaniline Chemical compound CC(C)C1=CC=CC=C1N YKOLZVXSPGIIBJ-UHFFFAOYSA-N 0.000 description 1
- LJMMVIIQWPAZJA-UHFFFAOYSA-N 2-[(2,6-difluorophenyl)hydrazinylidene]propanedinitrile Chemical compound FC1=CC=CC(F)=C1NN=C(C#N)C#N LJMMVIIQWPAZJA-UHFFFAOYSA-N 0.000 description 1
- FGGIUVZITPUMMQ-UHFFFAOYSA-N 2-[(2-bromophenyl)hydrazinylidene]propanedinitrile Chemical compound BrC1=CC=CC=C1NN=C(C#N)C#N FGGIUVZITPUMMQ-UHFFFAOYSA-N 0.000 description 1
- WJLRKYSNJJCEPP-UHFFFAOYSA-N 2-[(2-chlorophenyl)hydrazinylidene]propanedinitrile Chemical compound ClC1=CC=CC=C1NN=C(C#N)C#N WJLRKYSNJJCEPP-UHFFFAOYSA-N 0.000 description 1
- GARUNYYLNCCBTO-UHFFFAOYSA-N 2-[(2-methylphenyl)hydrazinylidene]propanedinitrile Chemical compound CC1=CC=CC=C1NN=C(C#N)C#N GARUNYYLNCCBTO-UHFFFAOYSA-N 0.000 description 1
- HALMTGNEUNUAMO-UHFFFAOYSA-N 2-[(2-phenylphenyl)hydrazinylidene]propanedinitrile Chemical compound N#CC(C#N)=NNC1=CC=CC=C1C1=CC=CC=C1 HALMTGNEUNUAMO-UHFFFAOYSA-N 0.000 description 1
- NKLLHAJZPMKPCU-UHFFFAOYSA-N 2-[(2-propan-2-ylphenyl)hydrazinylidene]propanedinitrile Chemical compound CC(C)C1=CC=CC=C1NN=C(C#N)C#N NKLLHAJZPMKPCU-UHFFFAOYSA-N 0.000 description 1
- GTVGGHQLKNCAMB-UHFFFAOYSA-N 2-[(3,4-dichlorophenyl)hydrazinylidene]propanedinitrile Chemical compound ClC1=CC=C(NN=C(C#N)C#N)C=C1Cl GTVGGHQLKNCAMB-UHFFFAOYSA-N 0.000 description 1
- NSZQYRFLYOLWGM-UHFFFAOYSA-N 2-[(3,4-difluorophenyl)hydrazinylidene]propanedinitrile Chemical compound FC1=CC=C(NN=C(C#N)C#N)C=C1F NSZQYRFLYOLWGM-UHFFFAOYSA-N 0.000 description 1
- QSPPKFSXMWSMTG-UHFFFAOYSA-N 2-[(3,4-dimethoxyphenyl)hydrazinylidene]propanedinitrile Chemical compound COC1=CC=C(NN=C(C#N)C#N)C=C1OC QSPPKFSXMWSMTG-UHFFFAOYSA-N 0.000 description 1
- PMBDYEGXPRAQBK-UHFFFAOYSA-N 2-[(3,5-dichlorophenyl)hydrazinylidene]propanedinitrile Chemical compound ClC1=CC(Cl)=CC(NN=C(C#N)C#N)=C1 PMBDYEGXPRAQBK-UHFFFAOYSA-N 0.000 description 1
- UHSPMWWBUAYGQI-UHFFFAOYSA-N 2-[(3-bromophenyl)hydrazinylidene]propanedinitrile Chemical compound BrC1=CC=CC(NN=C(C#N)C#N)=C1 UHSPMWWBUAYGQI-UHFFFAOYSA-N 0.000 description 1
- QAQDWMMJRXIJIY-UHFFFAOYSA-N 2-[(3-chloro-4-methoxyphenyl)hydrazinylidene]propanedinitrile Chemical compound COC1=CC=C(NN=C(C#N)C#N)C=C1Cl QAQDWMMJRXIJIY-UHFFFAOYSA-N 0.000 description 1
- FMDBRCCIHPBRBJ-UHFFFAOYSA-N 2-[(3-ethylphenyl)hydrazinylidene]propanedinitrile Chemical compound CCC1=CC=CC(NN=C(C#N)C#N)=C1 FMDBRCCIHPBRBJ-UHFFFAOYSA-N 0.000 description 1
- GSNHUMXNONIPHU-UHFFFAOYSA-N 2-[(3-fluoro-4-methoxyphenyl)hydrazinylidene]propanedinitrile Chemical compound COC1=CC=C(NN=C(C#N)C#N)C=C1F GSNHUMXNONIPHU-UHFFFAOYSA-N 0.000 description 1
- ZWKLFIGKZZGTCS-UHFFFAOYSA-N 2-[(3-fluorophenyl)hydrazinylidene]propanedinitrile Chemical compound FC1=CC=CC(NN=C(C#N)C#N)=C1 ZWKLFIGKZZGTCS-UHFFFAOYSA-N 0.000 description 1
- XPHHWVZARKXKST-UHFFFAOYSA-N 2-[(3-hydroxyphenyl)hydrazinylidene]propanedinitrile Chemical compound OC1=CC=CC(NN=C(C#N)C#N)=C1 XPHHWVZARKXKST-UHFFFAOYSA-N 0.000 description 1
- GCAZZHFRWGZJND-UHFFFAOYSA-N 2-[(3-iodophenyl)hydrazinylidene]propanedinitrile Chemical compound IC1=CC=CC(NN=C(C#N)C#N)=C1 GCAZZHFRWGZJND-UHFFFAOYSA-N 0.000 description 1
- FQOMUIUFPHDVGP-UHFFFAOYSA-N 2-[(3-methoxyphenyl)hydrazinylidene]propanedinitrile Chemical compound COC1=CC=CC(NN=C(C#N)C#N)=C1 FQOMUIUFPHDVGP-UHFFFAOYSA-N 0.000 description 1
- OVCCZAXWEQHDMP-UHFFFAOYSA-N 2-[(3-nitrophenyl)hydrazinylidene]propanedinitrile Chemical compound [O-][N+](=O)C1=CC=CC(NN=C(C#N)C#N)=C1 OVCCZAXWEQHDMP-UHFFFAOYSA-N 0.000 description 1
- GQROBIKAQWAGMI-UHFFFAOYSA-N 2-[(3-phenoxyphenyl)hydrazinylidene]propanedinitrile Chemical compound N#CC(C#N)=NNC1=CC=CC(OC=2C=CC=CC=2)=C1 GQROBIKAQWAGMI-UHFFFAOYSA-N 0.000 description 1
- JJDIGWXKILXPDT-UHFFFAOYSA-N 2-[(4-bromophenyl)hydrazinylidene]propanedinitrile Chemical compound BrC1=CC=C(NN=C(C#N)C#N)C=C1 JJDIGWXKILXPDT-UHFFFAOYSA-N 0.000 description 1
- KTGLAUQDVTYHBP-UHFFFAOYSA-N 2-[(4-iodophenyl)hydrazinylidene]propanedinitrile Chemical compound IC1=CC=C(NN=C(C#N)C#N)C=C1 KTGLAUQDVTYHBP-UHFFFAOYSA-N 0.000 description 1
- LFNURSLKYJLPOH-UHFFFAOYSA-N 2-[(4-methylsulfanylphenyl)hydrazinylidene]propanedinitrile Chemical compound CSC1=CC=C(NN=C(C#N)C#N)C=C1 LFNURSLKYJLPOH-UHFFFAOYSA-N 0.000 description 1
- XAYYDHQLURSMJT-UHFFFAOYSA-N 2-[(4-phenoxyphenyl)hydrazinylidene]propanedinitrile Chemical compound C1=CC(NN=C(C#N)C#N)=CC=C1OC1=CC=CC=C1 XAYYDHQLURSMJT-UHFFFAOYSA-N 0.000 description 1
- BBGPIZRSRGELJX-UHFFFAOYSA-N 2-[(5-aminopyridin-2-yl)-(2-hydroxyethyl)amino]ethanol Chemical compound NC1=CC=C(N(CCO)CCO)N=C1 BBGPIZRSRGELJX-UHFFFAOYSA-N 0.000 description 1
- JORZIVYWRDKLHD-UHFFFAOYSA-N 2-[(6-methoxy-1,3-benzothiazol-2-yl)hydrazinylidene]propanedinitrile Chemical compound COC1=CC=C2N=C(NN=C(C#N)C#N)SC2=C1 JORZIVYWRDKLHD-UHFFFAOYSA-N 0.000 description 1
- KJYJZGKBGAAITE-UHFFFAOYSA-N 2-[(9-ethylcarbazol-3-yl)hydrazinylidene]propanedinitrile Chemical compound N#CC(C#N)=NNC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 KJYJZGKBGAAITE-UHFFFAOYSA-N 0.000 description 1
- ATPMQLROPXAZQD-UHFFFAOYSA-N 2-[3-[2-(3,5-diaminopyrazol-4-ylidene)hydrazinyl]phenyl]sulfonylethanol Chemical compound NC1=NN=C(N)C1=NNC1=CC=CC(S(=O)(=O)CCO)=C1 ATPMQLROPXAZQD-UHFFFAOYSA-N 0.000 description 1
- LARIWECJXIBNDO-UHFFFAOYSA-N 2-[[2-(benzenesulfonyl)phenyl]hydrazinylidene]propanedinitrile Chemical compound C=1C=CC=C(NN=C(C#N)C#N)C=1S(=O)(=O)C1=CC=CC=C1 LARIWECJXIBNDO-UHFFFAOYSA-N 0.000 description 1
- LTYZNJGNMKTLEB-UHFFFAOYSA-N 2-[[2-(hydroxymethyl)phenyl]hydrazinylidene]propanedinitrile Chemical compound OCC1=CC=CC=C1NN=C(C#N)C#N LTYZNJGNMKTLEB-UHFFFAOYSA-N 0.000 description 1
- CFVQWSSWYUKQAR-UHFFFAOYSA-N 2-[[3-(trifluoromethyl)phenyl]hydrazinylidene]propanedinitrile Chemical compound FC(F)(F)C1=CC=CC(NN=C(C#N)C#N)=C1 CFVQWSSWYUKQAR-UHFFFAOYSA-N 0.000 description 1
- SMWADOQZAXGTAZ-UHFFFAOYSA-N 2-[[4-(diethoxyphosphorylmethyl)phenyl]hydrazinylidene]propanedinitrile Chemical compound CCOP(=O)(OCC)CC1=CC=C(NN=C(C#N)C#N)C=C1 SMWADOQZAXGTAZ-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- AOPBDRUWRLBSDB-UHFFFAOYSA-N 2-bromoaniline Chemical compound NC1=CC=CC=C1Br AOPBDRUWRLBSDB-UHFFFAOYSA-N 0.000 description 1
- LNEVUNYUJNORRV-UHFFFAOYSA-N 2-chloro-4-methoxyaniline Chemical compound COC1=CC=C(N)C(Cl)=C1 LNEVUNYUJNORRV-UHFFFAOYSA-N 0.000 description 1
- BAZVFQBTJPBRTJ-UHFFFAOYSA-N 2-chloro-5-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C(Cl)N=C1 BAZVFQBTJPBRTJ-UHFFFAOYSA-N 0.000 description 1
- AKCRQHGQIJBRMN-UHFFFAOYSA-N 2-chloroaniline Chemical compound NC1=CC=CC=C1Cl AKCRQHGQIJBRMN-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- WIQISTBTOQNVCE-UHFFFAOYSA-N 2-fluoro-1-methyl-4-nitrobenzene Chemical compound CC1=CC=C([N+]([O-])=O)C=C1F WIQISTBTOQNVCE-UHFFFAOYSA-N 0.000 description 1
- OMGSXGSDLPDHLJ-UHFFFAOYSA-N 2-fluoro-1-methyl-4-nitrobenzene;3-fluoro-4-(morpholin-4-ylmethyl)aniline Chemical compound CC1=CC=C([N+]([O-])=O)C=C1F.FC1=CC(N)=CC=C1CN1CCOCC1 OMGSXGSDLPDHLJ-UHFFFAOYSA-N 0.000 description 1
- JBIJLHTVPXGSAM-UHFFFAOYSA-N 2-naphthylamine Chemical compound C1=CC=CC2=CC(N)=CC=C21 JBIJLHTVPXGSAM-UHFFFAOYSA-N 0.000 description 1
- HLTDBMHJSBSAOM-UHFFFAOYSA-N 2-nitropyridine Chemical class [O-][N+](=O)C1=CC=CC=N1 HLTDBMHJSBSAOM-UHFFFAOYSA-N 0.000 description 1
- 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- TWBPWBPGNQWFSJ-UHFFFAOYSA-N 2-phenylaniline Chemical group NC1=CC=CC=C1C1=CC=CC=C1 TWBPWBPGNQWFSJ-UHFFFAOYSA-N 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- SDYWXFYBZPNOFX-UHFFFAOYSA-N 3,4-dichloroaniline Chemical compound NC1=CC=C(Cl)C(Cl)=C1 SDYWXFYBZPNOFX-UHFFFAOYSA-N 0.000 description 1
- AXNUZKSSQHTNPZ-UHFFFAOYSA-N 3,4-difluoroaniline Chemical compound NC1=CC=C(F)C(F)=C1 AXNUZKSSQHTNPZ-UHFFFAOYSA-N 0.000 description 1
- LGDHZCLREKIGKJ-UHFFFAOYSA-N 3,4-dimethoxyaniline Chemical compound COC1=CC=C(N)C=C1OC LGDHZCLREKIGKJ-UHFFFAOYSA-N 0.000 description 1
- UQRLKWGPEVNVHT-UHFFFAOYSA-N 3,5-dichloroaniline Chemical compound NC1=CC(Cl)=CC(Cl)=C1 UQRLKWGPEVNVHT-UHFFFAOYSA-N 0.000 description 1
- KQOIBXZRCYFZSO-UHFFFAOYSA-N 3,5-difluoroaniline Chemical compound NC1=CC(F)=CC(F)=C1 KQOIBXZRCYFZSO-UHFFFAOYSA-N 0.000 description 1
- ACGSZKYXDSPURU-UHFFFAOYSA-N 3-(morpholin-4-ylmethyl)-5-(trifluoromethyl)aniline Chemical compound FC(F)(F)C1=CC(N)=CC(CN2CCOCC2)=C1 ACGSZKYXDSPURU-UHFFFAOYSA-N 0.000 description 1
- ZTAKALNZCQKLTP-UHFFFAOYSA-N 3-(morpholin-4-ylmethyl)-5-nitroaniline Chemical compound [O-][N+](=O)C1=CC(N)=CC(CN2CCOCC2)=C1 ZTAKALNZCQKLTP-UHFFFAOYSA-N 0.000 description 1
- SEJNYLBEEMVJNN-UHFFFAOYSA-N 3-(piperidin-1-ylmethyl)aniline Chemical compound NC1=CC=CC(CN2CCCCC2)=C1 SEJNYLBEEMVJNN-UHFFFAOYSA-N 0.000 description 1
- VIUDTWATMPPKEL-UHFFFAOYSA-N 3-(trifluoromethyl)aniline Chemical compound NC1=CC=CC(C(F)(F)F)=C1 VIUDTWATMPPKEL-UHFFFAOYSA-N 0.000 description 1
- QUSFDIALRZIGOL-UHFFFAOYSA-N 3-[(2z)-2-(3-amino-5-morpholin-4-ylpyrazol-4-ylidene)hydrazinyl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC(NN=C2C(=NN=C2N)N2CCOCC2)=C1 QUSFDIALRZIGOL-UHFFFAOYSA-N 0.000 description 1
- LHSSZWORPJOQLP-UHFFFAOYSA-N 3-[(2z)-2-(3-amino-5-pyrrolidin-1-ylpyrazol-4-ylidene)hydrazinyl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC(NN=C2C(=NN=C2N)N2CCCC2)=C1 LHSSZWORPJOQLP-UHFFFAOYSA-N 0.000 description 1
- LTDCERVKAGJVMY-UHFFFAOYSA-N 3-[(2z)-2-(3-amino-5-pyrrolidin-1-ylpyrazol-4-ylidene)hydrazinyl]benzenesulfonamide Chemical compound C=1C=CC(S(N)(=O)=O)=CC=1NN=C1C(N)=NN=C1N1CCCC1 LTDCERVKAGJVMY-UHFFFAOYSA-N 0.000 description 1
- NJYXSHDYBYOZBK-UHFFFAOYSA-N 3-[2-[3-amino-5-(dimethylamino)pyrazol-4-ylidene]hydrazinyl]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC(NN=C2C(=NN=C2N)N(C)C)=C1 NJYXSHDYBYOZBK-UHFFFAOYSA-N 0.000 description 1
- ZNVHAQRPXAQKRU-UHFFFAOYSA-N 3-amino-5-nitrobenzoic acid Chemical compound NC1=CC(C(O)=O)=CC([N+]([O-])=O)=C1 ZNVHAQRPXAQKRU-UHFFFAOYSA-N 0.000 description 1
- VKLCYWUSCFPJMD-UHFFFAOYSA-N 3-amino-5-nitrobenzoic acid ethyl 3-amino-5-nitrobenzoate Chemical compound NC=1C=C(C(=O)O)C=C(C1)[N+](=O)[O-].C(C)OC(C1=CC(=CC(=C1)[N+](=O)[O-])N)=O VKLCYWUSCFPJMD-UHFFFAOYSA-N 0.000 description 1
- XFDUHJPVQKIXHO-UHFFFAOYSA-M 3-aminobenzoate Chemical compound NC1=CC=CC(C([O-])=O)=C1 XFDUHJPVQKIXHO-UHFFFAOYSA-M 0.000 description 1
- CWLKGDAVCFYWJK-UHFFFAOYSA-N 3-aminophenol Chemical compound NC1=CC=CC(O)=C1 CWLKGDAVCFYWJK-UHFFFAOYSA-N 0.000 description 1
- 229940018563 3-aminophenol Drugs 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- DHYHYLGCQVVLOQ-UHFFFAOYSA-N 3-bromoaniline Chemical compound NC1=CC=CC(Br)=C1 DHYHYLGCQVVLOQ-UHFFFAOYSA-N 0.000 description 1
- PNPCRKVUWYDDST-UHFFFAOYSA-N 3-chloroaniline Chemical compound NC1=CC=CC(Cl)=C1 PNPCRKVUWYDDST-UHFFFAOYSA-N 0.000 description 1
- AMKPQMFZCBTTAT-UHFFFAOYSA-N 3-ethylaniline Chemical compound CCC1=CC=CC(N)=C1 AMKPQMFZCBTTAT-UHFFFAOYSA-N 0.000 description 1
- LJWAPDSCYTZUJU-UHFFFAOYSA-N 3-fluoro-4-methoxyaniline Chemical compound COC1=CC=C(N)C=C1F LJWAPDSCYTZUJU-UHFFFAOYSA-N 0.000 description 1
- QZVQQUVWFIZUBQ-UHFFFAOYSA-N 3-fluoroaniline Chemical compound NC1=CC=CC(F)=C1 QZVQQUVWFIZUBQ-UHFFFAOYSA-N 0.000 description 1
- FFCSRWGYGMRBGD-UHFFFAOYSA-N 3-iodoaniline Chemical compound NC1=CC=CC(I)=C1 FFCSRWGYGMRBGD-UHFFFAOYSA-N 0.000 description 1
- VTFGJEYZCUWSAM-UHFFFAOYSA-N 3-methoxy-5-(trifluoromethyl)aniline Chemical compound COC1=CC(N)=CC(C(F)(F)F)=C1 VTFGJEYZCUWSAM-UHFFFAOYSA-N 0.000 description 1
- JJYPMNFTHPTTDI-UHFFFAOYSA-N 3-methylaniline Chemical class CC1=CC=CC(N)=C1 JJYPMNFTHPTTDI-UHFFFAOYSA-N 0.000 description 1
- ODCLHXGXGFBBTA-UHFFFAOYSA-N 3-nitro-5-(trifluoromethyl)benzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC(C(F)(F)F)=C1 ODCLHXGXGFBBTA-UHFFFAOYSA-N 0.000 description 1
- XJCVRTZCHMZPBD-UHFFFAOYSA-N 3-nitroaniline Chemical compound NC1=CC=CC([N+]([O-])=O)=C1 XJCVRTZCHMZPBD-UHFFFAOYSA-N 0.000 description 1
- UCSYVYFGMFODMY-UHFFFAOYSA-N 3-phenoxyaniline Chemical compound NC1=CC=CC(OC=2C=CC=CC=2)=C1 UCSYVYFGMFODMY-UHFFFAOYSA-N 0.000 description 1
- AYQRNZDLRDLAHE-UHFFFAOYSA-N 4-(1,2,4-triazin-3-ylhydrazinylidene)pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=NC=CN=N1 AYQRNZDLRDLAHE-UHFFFAOYSA-N 0.000 description 1
- GDWQBNAUUYCWIC-UHFFFAOYSA-N 4-(1,3-thiazol-2-ylhydrazinylidene)pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=NC=CS1 GDWQBNAUUYCWIC-UHFFFAOYSA-N 0.000 description 1
- KAHCKSWFRSBZRG-UHFFFAOYSA-N 4-(2-morpholin-4-ylethylhydrazinylidene)pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNCCN1CCOCC1 KAHCKSWFRSBZRG-UHFFFAOYSA-N 0.000 description 1
- IIRHTTDXNXCWHP-UHFFFAOYSA-N 4-(3-methyl-4-nitrophenyl)morpholine Chemical compound C1=C([N+]([O-])=O)C(C)=CC(N2CCOCC2)=C1 IIRHTTDXNXCWHP-UHFFFAOYSA-N 0.000 description 1
- ZVAYUUUQOCPZCZ-UHFFFAOYSA-N 4-(diethoxyphosphorylmethyl)aniline Chemical compound CCOP(=O)(OCC)CC1=CC=C(N)C=C1 ZVAYUUUQOCPZCZ-UHFFFAOYSA-N 0.000 description 1
- YKFROQCFVXOUPW-UHFFFAOYSA-N 4-(methylthio) aniline Chemical compound CSC1=CC=C(N)C=C1 YKFROQCFVXOUPW-UHFFFAOYSA-N 0.000 description 1
- SOUFDUGXFLPISS-UHFFFAOYSA-N 4-(morpholin-4-ylhydrazinylidene)pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNN1CCOCC1 SOUFDUGXFLPISS-UHFFFAOYSA-N 0.000 description 1
- POPCVBLPZKHRCX-UHFFFAOYSA-N 4-(naphthalen-1-ylhydrazinylidene)pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=CC2=CC=CC=C12 POPCVBLPZKHRCX-UHFFFAOYSA-N 0.000 description 1
- OKZNBFAXFGTZRH-UHFFFAOYSA-N 4-(phenylhydrazinylidene)pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=CC=C1 OKZNBFAXFGTZRH-UHFFFAOYSA-N 0.000 description 1
- CYEPDOGFHJWUFH-UHFFFAOYSA-N 4-(piperidin-4-ylmethylhydrazinylidene)pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNCC1CCNCC1 CYEPDOGFHJWUFH-UHFFFAOYSA-N 0.000 description 1
- NIQRDODNZBKHIW-UHFFFAOYSA-N 4-(pyridin-4-ylhydrazinylidene)pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=NC=C1.NC1=NN=C(N)C1=NNC1=CC=NC=C1 NIQRDODNZBKHIW-UHFFFAOYSA-N 0.000 description 1
- CIVHPCTUPSAMHN-UHFFFAOYSA-N 4-[(2z)-2-(3-amino-5-pyrrolidin-1-ylpyrazol-4-ylidene)hydrazinyl]benzenesulfonamide Chemical compound C=1C=C(S(N)(=O)=O)C=CC=1NN=C1C(N)=NN=C1N1CCCC1 CIVHPCTUPSAMHN-UHFFFAOYSA-N 0.000 description 1
- OVKFPWXRSHFTPD-UHFFFAOYSA-N 4-[(2z)-2-[3-amino-5-(4-methylpiperazin-1-yl)pyrazol-4-ylidene]hydrazinyl]benzenesulfonamide Chemical compound C1CN(C)CCN1C1=NN=C(N)C1=NNC1=CC=C(S(N)(=O)=O)C=C1 OVKFPWXRSHFTPD-UHFFFAOYSA-N 0.000 description 1
- LKLZCFXKZBZDMZ-UHFFFAOYSA-N 4-[(3-fluorophenyl)diazenyl]-5-methyl-1H-pyrazol-3-amine Chemical compound CC1=NNC(N)=C1N=NC1=CC=CC(F)=C1 LKLZCFXKZBZDMZ-UHFFFAOYSA-N 0.000 description 1
- KTRURCMSXBBQDM-UHFFFAOYSA-N 4-[(4-butylphenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound C1=CC(CCCC)=CC=C1NN=C1C(N)=NN=C1N KTRURCMSXBBQDM-UHFFFAOYSA-N 0.000 description 1
- XTONCZCIDRYXDH-UHFFFAOYSA-N 4-[(4-chlorophenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound NC1=NN=C(N)C1=NNC1=CC=C(Cl)C=C1 XTONCZCIDRYXDH-UHFFFAOYSA-N 0.000 description 1
- LTXPTEHDYDGWHR-UHFFFAOYSA-N 4-[(4-methylphenyl)hydrazinylidene]pyrazole-3,5-diamine Chemical compound C1=CC(C)=CC=C1NN=C1C(N)=NN=C1N LTXPTEHDYDGWHR-UHFFFAOYSA-N 0.000 description 1
- CVVNQGVHNHHMDH-UHFFFAOYSA-N 4-[2-(3,5-diaminopyrazol-4-ylidene)hydrazinyl]-n-pyrimidin-2-ylbenzenesulfonamide Chemical compound NC1=NN=C(N)C1=NNC1=CC=C(S(=O)(=O)NC=2N=CC=CN=2)C=C1 CVVNQGVHNHHMDH-UHFFFAOYSA-N 0.000 description 1
- ZNHPTFLPMBFEHP-UHFFFAOYSA-N 4-[2-(3,5-diaminopyrazol-4-ylidene)hydrazinyl]benzenesulfonic acid Chemical compound NC1=NN=C(N)C1=NNC1=CC=C(S(O)(=O)=O)C=C1 ZNHPTFLPMBFEHP-UHFFFAOYSA-N 0.000 description 1
- YBZULGHRMLTAFP-UHFFFAOYSA-N 4-[2-(3,5-diaminopyrazol-4-ylidene)hydrazinyl]naphthalene-1-sulfonic acid Chemical compound NC1=NN=C(N)C1=NNC1=CC=C(S(O)(=O)=O)C2=CC=CC=C12 YBZULGHRMLTAFP-UHFFFAOYSA-N 0.000 description 1
- GFFZFWAUXAFCSY-UHFFFAOYSA-N 4-[2-(4-nitrophenyl)ethyl]morpholine Chemical compound C1=CC([N+](=O)[O-])=CC=C1CCN1CCOCC1 GFFZFWAUXAFCSY-UHFFFAOYSA-N 0.000 description 1
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
- WDFQBORIUYODSI-UHFFFAOYSA-N 4-bromoaniline Chemical compound NC1=CC=C(Br)C=C1 WDFQBORIUYODSI-UHFFFAOYSA-N 0.000 description 1
- LIUKLAQDPKYBCP-UHFFFAOYSA-N 4-bromonaphthalen-1-amine Chemical compound C1=CC=C2C(N)=CC=C(Br)C2=C1 LIUKLAQDPKYBCP-UHFFFAOYSA-N 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- SKDUMUXUMJDPMS-UHFFFAOYSA-N 4-fluoro-2-(morpholin-4-ylmethyl)aniline Chemical compound NC1=CC=C(F)C=C1CN1CCOCC1 SKDUMUXUMJDPMS-UHFFFAOYSA-N 0.000 description 1
- WGRSDSXOKBZEAZ-UHFFFAOYSA-N 4-fluoro-2-methyl-1-nitrobenzene 4-[(5-fluoro-2-nitrophenyl)methyl]morpholine Chemical compound FC=1C=CC(=C(C1)C)[N+](=O)[O-].FC=1C=CC(=C(CN2CCOCC2)C1)[N+](=O)[O-] WGRSDSXOKBZEAZ-UHFFFAOYSA-N 0.000 description 1
- PGFQDLOMDIBAPY-UHFFFAOYSA-N 4-fluoro-3-(trifluoromethyl)aniline Chemical compound NC1=CC=C(F)C(C(F)(F)F)=C1 PGFQDLOMDIBAPY-UHFFFAOYSA-N 0.000 description 1
- KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
- PCNFLKVWBDNNOW-UHFFFAOYSA-N 4-hydrazinylbenzoic acid Chemical compound NNC1=CC=C(C(O)=O)C=C1 PCNFLKVWBDNNOW-UHFFFAOYSA-N 0.000 description 1
- VLVCDUSVTXIWGW-UHFFFAOYSA-N 4-iodoaniline Chemical compound NC1=CC=C(I)C=C1 VLVCDUSVTXIWGW-UHFFFAOYSA-N 0.000 description 1
- WOYZXEVUWXQVNV-UHFFFAOYSA-N 4-phenoxyaniline Chemical compound C1=CC(N)=CC=C1OC1=CC=CC=C1 WOYZXEVUWXQVNV-UHFFFAOYSA-N 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- ODGIMMLDVSWADK-UHFFFAOYSA-N 4-trifluoromethylaniline Chemical compound NC1=CC=C(C(F)(F)F)C=C1 ODGIMMLDVSWADK-UHFFFAOYSA-N 0.000 description 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
- GLBPVQBOYDAZDS-UHFFFAOYSA-N 5-[2-(3,5-diaminopyrazol-4-ylidene)hydrazinyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1NN=C1C(N)=NN=C1N GLBPVQBOYDAZDS-UHFFFAOYSA-N 0.000 description 1
- JISYBKQCYRYPOF-UHFFFAOYSA-N 5-methyl-4-(phenylhydrazinylidene)pyrazol-3-amine Chemical compound CC1=NN=C(N)C1=NNC1=CC=CC=C1 JISYBKQCYRYPOF-UHFFFAOYSA-N 0.000 description 1
- BXZPSERJJMAPSV-UHFFFAOYSA-N 5-nitro-2,1,3-benzothiadiazole Chemical compound C1=C([N+](=O)[O-])C=CC2=NSN=C21 BXZPSERJJMAPSV-UHFFFAOYSA-N 0.000 description 1
- NZTCEWZBMOTKCJ-UHFFFAOYSA-N 6-(4-methylpiperazin-1-yl)pyridin-3-amine Chemical compound C1CN(C)CCN1C1=CC=C(N)C=N1 NZTCEWZBMOTKCJ-UHFFFAOYSA-N 0.000 description 1
- VVTSPTCBHTWXMD-UHFFFAOYSA-N 6-morpholin-4-ylpyridin-3-amine Chemical compound N1=CC(N)=CC=C1N1CCOCC1 VVTSPTCBHTWXMD-UHFFFAOYSA-N 0.000 description 1
- WONYQZCHGNGJRW-UHFFFAOYSA-N 6-piperidin-1-ylpyridin-3-amine Chemical compound N1=CC(N)=CC=C1N1CCCCC1 WONYQZCHGNGJRW-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- JBNOVHJXQSHGRL-UHFFFAOYSA-N 7-amino-4-(trifluoromethyl)coumarin Chemical compound FC(F)(F)C1=CC(=O)OC2=CC(N)=CC=C21 JBNOVHJXQSHGRL-UHFFFAOYSA-N 0.000 description 1
- BUNGCZLFHHXKBX-UHFFFAOYSA-N 8-methoxypsoralen Natural products C1=CC(=O)OC2=C1C=C1CCOC1=C2OC BUNGCZLFHHXKBX-UHFFFAOYSA-N 0.000 description 1
- OXEUETBFKVCRNP-UHFFFAOYSA-N 9-ethyl-3-carbazolamine Chemical compound NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 OXEUETBFKVCRNP-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000008516 Capsule Opacification Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- UGTJLJZQQFGTJD-UHFFFAOYSA-N Carbonylcyanide-3-chlorophenylhydrazone Chemical compound ClC1=CC=CC(NN=C(C#N)C#N)=C1 UGTJLJZQQFGTJD-UHFFFAOYSA-N 0.000 description 1
- 101800005309 Carboxy-terminal peptide Proteins 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
- 208000006402 Ductal Carcinoma Diseases 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 241001443715 Fusarium oxysporum f. sp. conglutinans Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000000265 Lobular Carcinoma Diseases 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 1
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 229910015221 MoCl5 Inorganic materials 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- JHLPFOQDEWHCBR-UHFFFAOYSA-N N1=CC=CC2=CC(=CC=C12)NN=C1C(=NN=C1N)N.N1=CC=CC2=CC(=CC=C12)NN=C1C(=NN=C1N)N Chemical compound N1=CC=CC2=CC(=CC=C12)NN=C1C(=NN=C1N)N.N1=CC=CC2=CC(=CC=C12)NN=C1C(=NN=C1N)N JHLPFOQDEWHCBR-UHFFFAOYSA-N 0.000 description 1
- SULARNLIOIFYMQ-UHFFFAOYSA-N NC1=NN=C(N)C1=NNC1=CC=C(O)C(CN2CCOCC2)=C1 Chemical compound NC1=NN=C(N)C1=NNC1=CC=C(O)C(CN2CCOCC2)=C1 SULARNLIOIFYMQ-UHFFFAOYSA-N 0.000 description 1
- GIAQFFDPSYQXKO-UHFFFAOYSA-N NC1=NN=C(N)C1=NNC1=NC=CN1 Chemical compound NC1=NN=C(N)C1=NNC1=NC=CN1 GIAQFFDPSYQXKO-UHFFFAOYSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 102100027069 Odontogenic ameloblast-associated protein Human genes 0.000 description 1
- 101710091533 Odontogenic ameloblast-associated protein Proteins 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000007135 Retinal Neovascularization Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010042658 Sweat gland tumour Diseases 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 239000003875 Wang resin Substances 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- QQPGGBNMTNDKEY-UHFFFAOYSA-N [2-butyl-5-chloro-3-[[4-[2-(2-trityltetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=NN(N=N2)C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)C=C1 QQPGGBNMTNDKEY-UHFFFAOYSA-N 0.000 description 1
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
- UJIGODSAJQOXCP-UHFFFAOYSA-N [N+](=O)([O-])C=1C=C(C=CC1)NN=C1C(=NN=C1N)N.[N+](=O)([O-])C=1C=C(C=CC1)NN=C1C(=NN=C1N)N Chemical compound [N+](=O)([O-])C=1C=C(C=CC1)NN=C1C(=NN=C1N)N.[N+](=O)([O-])C=1C=C(C=CC1)NN=C1C(=NN=C1N)N UJIGODSAJQOXCP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 208000018234 adnexal spiradenoma/cylindroma of a sweat gland Diseases 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229940098174 alkeran Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002257 antimetastatic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000005756 apoptotic signaling Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000006470 autoimmune attack Effects 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WARCRYXKINZHGQ-UHFFFAOYSA-N benzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1 WARCRYXKINZHGQ-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229940108502 bicnu Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 201000003714 breast lobular carcinoma Diseases 0.000 description 1
- 125000004799 bromophenyl group Chemical group 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 1
- 229960000932 candesartan Drugs 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 238000013130 cardiovascular surgery Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- KNSDLOIIFWEGLS-UHFFFAOYSA-N chembl217734 Chemical compound NC1=NNC(N)=C1N=NC1=CC=CC([N+]([O-])=O)=C1 KNSDLOIIFWEGLS-UHFFFAOYSA-N 0.000 description 1
- NCWCSLXGDWIAIT-UHFFFAOYSA-N chembl383939 Chemical compound NC1=NNC(N)=C1N=NC1=CC=C(C(O)=O)C=C1 NCWCSLXGDWIAIT-UHFFFAOYSA-N 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229950006523 cilexetil Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000011280 coal tar Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- VTDCYOLLYVAJSY-UHFFFAOYSA-N cyclohexyl propan-2-yl carbonate Chemical compound CC(C)OC(=O)OC1CCCCC1 VTDCYOLLYVAJSY-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 125000005507 decahydroisoquinolyl group Chemical group 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 150000008049 diazo compounds Chemical class 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 201000007273 ductal carcinoma in situ Diseases 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 229950005127 erbumine Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- FSJDMZWOBVIXBE-UHFFFAOYSA-N ethyl 4-[2-(dicyanomethylidene)hydrazinyl]benzoate Chemical compound CCOC(=O)C1=CC=C(NN=C(C#N)C#N)C=C1 FSJDMZWOBVIXBE-UHFFFAOYSA-N 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 208000024711 extrinsic asthma Diseases 0.000 description 1
- 229960004979 fampridine Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 125000003844 furanonyl group Chemical group 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 229940096120 hydrea Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- KJDJPXUIZYHXEZ-UHFFFAOYSA-N hydrogen sulfate;methylaminoazanium Chemical compound CN[NH3+].OS([O-])(=O)=O KJDJPXUIZYHXEZ-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 229960001195 imidapril Drugs 0.000 description 1
- KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 208000030776 invasive breast carcinoma Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000005427 lymphocyte apoptotic process Effects 0.000 description 1
- 208000007282 lymphomatoid papulosis Diseases 0.000 description 1
- 230000001589 lymphoproliferative effect Effects 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- NCBZRJODKRCREW-UHFFFAOYSA-N m-anisidine Chemical compound COC1=CC=CC(N)=C1 NCBZRJODKRCREW-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 230000027739 mammary gland involution Effects 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 230000006510 metastatic growth Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960004469 methoxsalen Drugs 0.000 description 1
- SQBBOVROCFXYBN-UHFFFAOYSA-N methoxypsoralen Natural products C1=C2OC(=O)C(OC)=CC2=CC2=C1OC=C2 SQBBOVROCFXYBN-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- BLWYXBNNBYXPPL-UHFFFAOYSA-N methyl pyrrolidine-2-carboxylate Chemical compound COC(=O)C1CCCN1 BLWYXBNNBYXPPL-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- GICWIDZXWJGTCI-UHFFFAOYSA-I molybdenum pentachloride Chemical compound Cl[Mo](Cl)(Cl)(Cl)Cl GICWIDZXWJGTCI-UHFFFAOYSA-I 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- IHAMPPARILYWJA-UHFFFAOYSA-N n-[4-[2-(3,5-diaminopyrazol-4-ylidene)hydrazinyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1NN=C1C(N)=NN=C1N IHAMPPARILYWJA-UHFFFAOYSA-N 0.000 description 1
- JAZSJMJSRZNSFV-UHFFFAOYSA-N n-[[3-(ethylamino)-5-methylpyrazol-4-ylidene]amino]pyridin-3-amine Chemical compound CCNC1=NN=C(C)C1=NNC1=CC=CN=C1 JAZSJMJSRZNSFV-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- YBOSMNMCTQVJOH-UHFFFAOYSA-N n-methoxy-3-nitroaniline Chemical compound CONC1=CC=CC([N+]([O-])=O)=C1 YBOSMNMCTQVJOH-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- WHQDPSGUFIHZTE-UHFFFAOYSA-N naphthalen-2-ol Chemical compound C1=CC=CC2=CC(O)=CC=C21.C1=CC=CC2=CC(O)=CC=C21 WHQDPSGUFIHZTE-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229940086322 navelbine Drugs 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 210000001982 neural crest cell Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Substances [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
- 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- RZXMPPFPUUCRFN-UHFFFAOYSA-N p-toluidine Chemical compound CC1=CC=C(N)C=C1 RZXMPPFPUUCRFN-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960002582 perindopril Drugs 0.000 description 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
- 229940067157 phenylhydrazine Drugs 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- RJSRSRITMWVIQT-UHFFFAOYSA-N quinolin-6-amine Chemical compound N1=CC=CC2=CC(N)=CC=C21 RJSRSRITMWVIQT-UHFFFAOYSA-N 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 102200001405 rs377584435 Human genes 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- YZMCKZRAOLZXAZ-UHFFFAOYSA-N sulfisomidine Chemical compound CC1=NC(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 YZMCKZRAOLZXAZ-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 229910052717 sulfur Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 125000006090 thiamorpholinyl sulfone group Chemical group 0.000 description 1
- 125000006089 thiamorpholinyl sulfoxide group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 229960002051 trandolapril Drugs 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229960003895 verteporfin Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229940061392 visudyne Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/04—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33526501P | 2001-11-30 | 2001-11-30 | |
| US60/335,265 | 2001-11-30 | ||
| US10/077,238 US7105503B2 (en) | 2000-04-07 | 2002-02-15 | Pyrazole compounds |
| US10/077,238 | 2002-02-15 | ||
| PCT/CA2002/001583 WO2003045379A1 (en) | 2001-11-30 | 2002-10-18 | Hydrazonopyrazole derivatives and their use as therapeutics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2468562A1 CA2468562A1 (en) | 2003-06-05 |
| CA2468562C true CA2468562C (en) | 2011-12-20 |
Family
ID=26759053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2468562A Expired - Fee Related CA2468562C (en) | 2001-11-30 | 2002-10-18 | Hydrazonopyrazole derivatives and their use as therapeutics |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US7875728B2 (https=) |
| EP (1) | EP1450791A1 (https=) |
| JP (1) | JP2005519878A (https=) |
| CN (1) | CN1671379A (https=) |
| AU (2) | AU2002333114B2 (https=) |
| CA (1) | CA2468562C (https=) |
| MX (1) | MXPA04005204A (https=) |
| RU (1) | RU2332996C2 (https=) |
| WO (1) | WO2003045379A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CY2010012I2 (el) | 2000-05-25 | 2020-05-29 | Novartis Ag | Μιμητικα θρομβοποιητινης |
| RU2332996C2 (ru) | 2001-11-30 | 2008-09-10 | КьюЭлТи Инк. | Производные гидразонпиразола и их применение в качестве лекарственного средства |
| TWI280128B (en) | 2002-05-22 | 2007-05-01 | Smithkline Beecham Corp | 3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
| TW200526638A (en) | 2003-10-22 | 2005-08-16 | Smithkline Beecham Corp | 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline |
| GB0419416D0 (en) * | 2004-09-01 | 2004-10-06 | Inst Of Ex Botany Ascr | 4-Arylazo-3,5-Diamino-Pyrazole compounds and use thereof |
| ECSP077628A (es) | 2007-05-03 | 2008-12-30 | Smithkline Beechman Corp | Nueva composición farmacéutica |
| GB0908614D0 (en) | 2009-05-19 | 2009-06-24 | Tayside Flow Technologies Ltd | A vascular graft |
| MX2011012668A (es) | 2009-05-29 | 2011-12-16 | Glaxosmithkline Llc | Metodos de administracion de compuestos agonistas de trombopoyetina. |
| RU2546005C2 (ru) | 2009-09-15 | 2015-04-10 | Кью Эл Ти ИНК. | Фармацевтические составы, содержащие 9-цис-ретиниловые сложные эфиры в липидном наполнителе |
| US9173856B2 (en) | 2010-04-19 | 2015-11-03 | Qlt Inc. | Therapeutic regimen and methods for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency |
| CA2865935C (en) | 2012-03-01 | 2021-12-14 | Qlt Inc. | Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency |
| CN104958288B (zh) * | 2015-06-26 | 2017-08-11 | 苏州大学 | 一种血小板抑制剂及其在制备抗血小板疾病药物中的应用 |
| KR102128509B1 (ko) * | 2018-12-19 | 2020-07-01 | 한국과학기술연구원 | 말단 아민기에 아릴 또는 헤테로아릴기가 치환된 신규한 히드라존 유도체 및 이의 용도 |
| KR102356644B1 (ko) * | 2020-06-19 | 2022-01-28 | 한국과학기술연구원 | 신규한 옥소피리다지닐-페닐-카르보노하이드라조노일 디시아나이드 화합물 및 이의 용도 |
| EP4169916A4 (en) * | 2020-06-19 | 2024-07-10 | Korea Institute of Science and Technology | CARBONOHYDRAZONOYL DICYANIDE COMPOUND COMPRISING AT LEAST TWO TYPES OF ARYL OR HETEROARYL LINKED BY A NOVEL LINKER, AND USE THEREOF |
| KR102633087B1 (ko) * | 2020-06-19 | 2024-02-05 | 한국과학기술연구원 | 신규한 융합헤테로고리-카르보노하이드라조노일 디시아나이드 화합물 및 이의 용도 |
| CN113583110B (zh) * | 2021-08-19 | 2023-07-21 | 华南农业大学 | 一种苯并三唑半抗原、人工抗原和抗体及其制备方法与应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH373842A (de) * | 1959-09-11 | 1963-12-15 | Geigy Ag J R | Verfahren zur Herstellung von in Wasser dispergierbaren, schwer löslichen Azofarbstoffen |
| NL127251C (https=) * | 1965-01-15 | |||
| DE2248738A1 (de) * | 1972-10-05 | 1974-04-11 | Bayer Ag | Kationische diazacyaninfarbstoffe |
| SU1162799A1 (ru) * | 1982-07-09 | 1985-06-23 | Витебский государственный медицинский институт | Способ получени 4-арилгидразонов пиразолидинтриона-3,4,5 |
| US4562248A (en) * | 1983-11-25 | 1985-12-31 | Eastman Kodak Company | Azo dyes from unsubstituted or substituted 3-amino-pyridine and aryl or heterocyclic couplers |
| CA2369076A1 (en) | 2000-02-05 | 2001-08-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compositions useful as inhibitors of erk |
| HUP0202332A2 (en) | 2000-02-05 | 2002-10-28 | Vertex Pharma | Pyrazole compositions useful as inhibitors of erk |
| WO2001056557A2 (en) | 2000-02-05 | 2001-08-09 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of erk |
| US6436915B1 (en) * | 2000-04-07 | 2002-08-20 | Kinetek Pharmaceuticals, Inc. | Pyrazole compounds |
| US6214813B1 (en) * | 2000-04-07 | 2001-04-10 | Kinetek Pharmaceuticals, Inc. | Pyrazole compounds |
| GB0102687D0 (en) | 2001-02-02 | 2001-03-21 | Pharmacia & Upjohn Spa | Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them |
| RU2332996C2 (ru) | 2001-11-30 | 2008-09-10 | КьюЭлТи Инк. | Производные гидразонпиразола и их применение в качестве лекарственного средства |
| EP1456180B1 (en) | 2001-12-21 | 2007-10-03 | Vernalis (Cambridge) Limited | 3-(2,4)dihydroxyphenyl-4-phenylpyrazoles and their medical use |
-
2002
- 2002-10-18 RU RU2004119957/04A patent/RU2332996C2/ru not_active IP Right Cessation
- 2002-10-18 JP JP2003546881A patent/JP2005519878A/ja not_active Ceased
- 2002-10-18 CA CA2468562A patent/CA2468562C/en not_active Expired - Fee Related
- 2002-10-18 WO PCT/CA2002/001583 patent/WO2003045379A1/en not_active Ceased
- 2002-10-18 US US10/497,046 patent/US7875728B2/en not_active Expired - Fee Related
- 2002-10-18 MX MXPA04005204A patent/MXPA04005204A/es unknown
- 2002-10-18 EP EP02803715A patent/EP1450791A1/en not_active Withdrawn
- 2002-10-18 AU AU2002333114A patent/AU2002333114B2/en not_active Ceased
- 2002-10-18 CN CNA02827752XA patent/CN1671379A/zh active Pending
-
2008
- 2008-12-04 AU AU2008252075A patent/AU2008252075A1/en not_active Abandoned
-
2010
- 2010-12-23 US US12/977,794 patent/US8445694B2/en not_active Expired - Fee Related
-
2013
- 2013-04-29 US US13/872,819 patent/US20140107125A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002333114A1 (en) | 2003-06-10 |
| RU2332996C2 (ru) | 2008-09-10 |
| MXPA04005204A (es) | 2005-11-04 |
| CN1671379A (zh) | 2005-09-21 |
| WO2003045379A1 (en) | 2003-06-05 |
| AU2002333114B2 (en) | 2008-09-04 |
| EP1450791A1 (en) | 2004-09-01 |
| US8445694B2 (en) | 2013-05-21 |
| US7875728B2 (en) | 2011-01-25 |
| US20140107125A1 (en) | 2014-04-17 |
| AU2008252075A1 (en) | 2009-01-08 |
| US20050272709A1 (en) | 2005-12-08 |
| US20110237783A1 (en) | 2011-09-29 |
| JP2005519878A (ja) | 2005-07-07 |
| RU2004119957A (ru) | 2005-07-20 |
| CA2468562A1 (en) | 2003-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8445694B2 (en) | Hydrazonopyrazole derivatives and their use as therapeutics | |
| AU2003254650B2 (en) | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents | |
| US7105503B2 (en) | Pyrazole compounds | |
| US7790761B2 (en) | Blockade of voltage dependent sodium channels | |
| AU2002313633B2 (en) | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs | |
| TWI415845B (zh) | 用於治療與5-ht2a血清素受體相關聯病症之作為5-ht2a血清素受體之調節劑的吡唑衍生物 | |
| JP2003506368A (ja) | 2−ピラゾリン−5−オン | |
| IL223744A (en) | Annals 4-pyrid-2-ram-5- (triazolo [5,1- a] pyrid-6-ram) - and 5-pyrid-2-ram-4- (triazulu [5,1- a] pyrid- 6-il) -2-methyl-imidazole and their pharmaceutical preparations | |
| JP2004511470A (ja) | 蛋白キナーゼ阻害薬 | |
| KR20020015034A (ko) | 티로신 키나제 억제제로서의 치환된1,4-디하이드로인데노[1,2-c]피라졸 | |
| CN110835333A (zh) | 苯并咪唑取代唑类化合物及其用途 | |
| BR112019026478A2 (pt) | compostos para modulação da atividade de s1p1 e métodos de uso dos mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20201019 |